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I. INTRODUCTION     1 
I. INTRODUCTION 
Laron Syndrome (LS) is a very rare autosomal recessive hereditary disorder – just 
a few hundred people are affected worldwide (Rosenfeld, Rosenbloom et al. 1994). 
LS is caused by mutations of the growth hormone receptor gene (GHR) diminishing 
the binding or signal transduction of growth hormone (GH) action (Eshet, Laron et 
al. 1984). Therefore, LS patients exhibit low levels of circulating insulin-like 
growth factor 1 (IGF1) as its production is stimulated by GH action (reviewed in 
Laron 2004). In contrast, levels of circulating GH are elevated, as the negative 
feedback loop by IGF1 is diminished (Zhou, Xu et al. 1997). The phenotypic 
consequences of growth hormone receptor deficiency (GHRD) involve dwarfism, 
obesity and disturbances in glucose homeostasis (reviewed in List, Sackmann-Sala 
et al. 2011). The investigation of a very isolated cohort of LS patients in Ecuador 
(Guevara-Aguirre, Rosenbloom et al. 1993), draw special interest towards this 
syndrome as affected patients seemed to be protected against cancer and diabetes 
and effects associated with longevity were observed (Guevara-Aguirre, 
Balasubramanian et al. 2011). The Laron mouse, generated by targeted disruption 
of the Ghr gene (Zhou, Xu et al. 1997), resembles hallmarks of the phenotype of 
human LS and helped to develop therapeutic strategies and to investigate the 
function of the GH–IGF1 interaction. An interesting observation was the increased 
life expectancy, for which the Laron mouse model received the Methuselah Mouse 
Prize for life span extension (Bartke and Brown-Borg 2004). Nevertheless, the 
Laron mouse does not resemble all important aspects of the human phenotype of 
Laron syndrome due to taxonomic differences including the maturation of the 
endocrine growth axis, bone growth and transient changes in glucose homeostasis. 
As the pig has become a widely used animal model and provides the opportunity to 
close the evolutionary gap between mice and humans, we decided to generate a 
genetically tailored pig model for LS using the CRISPR/Cas technology.  
The aim of this thesis was to characterize the phenotype of the GHR-knockout (KO) 
pig regarding growth impairment, endocrine alterations and effects on metabolism. 
Driven by the idea, that pro-aging effects resulting from GHRD might be associated 
with an increased insulin sensitivity and the absence of malignant factors, we 
investigated the hepatic signaling of the insulin receptor and GHR associated 
signaling pathways including mTOR.  
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II.  REVIEW OF THE LITERATURE 
1. The endocrine growth axis 
Dwarfism is a main characteristic of the LS. Dwarfism can result from multiple 
causes such as skeletal disorders, chromosome alterations, metabolic and disorders 
affecting the endocrine growth axis (Rimoin 1976). In brief, the endocrine growth 
axis includes GH which is secreted by the pituitary gland under control of several 
feedback mechanisms involving circulating factors and the hypothalamus. GH 
promotes growth mostly via the stimulation of IGF1 production, but also by 
independent actions. The growth hormone receptor is required to maintain the 
actions of GH. 
1.1. Growth hormone 
Somatotrophic cells in the pars distalis of the pituitary gland release GH into the 
circulation. The secretion of GH is under the control of complex feedback 
mechanisms and occurs in a pulsatile manner, with a circadian rhythm involved 
leading to a nocturnal maximum of GH which was observed in human studies 
(Honda, Takahashi et al. 1969). The secretion pattern of GH is affected by both age 
and sex. GH promotes growth either directly or via the induced production of IGF1 
by the liver (Kaplan and Cohen 2007), what is called the GH/IGF axis. The levels 
of circulating IGF1 and GH itself influence the GH – synonymous somatotropin - 
secretion on hypothalamic level. The hypothalamus controls GH secretion by 
growth hormone releasing hormone (GHRH; synonymous somatoliberin), which 
stimulates GH secretion by the pituitary gland, and somatostatin (synonymous 
growth hormone inhibiting hormone (GHIH)), which inhibits the secretion of GH. 
The interplay of those noncompetitive antagonists results in the pulsatility of GH 
secretion (Varela-Nieto and Chowen 2005).  
Due to inflammation, trauma, neoplasia or idiopathic insults, hypopituitarism can 
be developed, which is one of the most important endocrine disorders leading to 
dwarfism. Facing hypopituitarism, GH secretion and its levels in circulation are 
diminished (Schneider, Aimaretti et al. 2007). In contrast, GHRD results in 
increased GH levels (reviewed in Laron and Kopchick 2011). 
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1.2. Insulin-like growth factors  
The insulin like growth factors 1 and 2 are potent factors stimulating growth. They 
share 50% homology with insulin and are able to stimulate glucose uptake in muscle 
and fat cells (reviewed in Varela-Nieto and Chowen 2005). IGF1 is a potent growth 
factor throughout postnatal development, whereas IGF2 mostly stimulates 
intrauterine growth (Baker, Liu et al. 1993). In contrast to IGF2, the production of 
IGF1 by the liver depends on GH. In the circulation, IGFs are bound to six different 
high-affinity IGF binding proteins (IGFBPs). The IGFBPs bind IGF1 or IGF2 with 
different affinities, modulating the bioactivity of IGFs by providing a reservoir of 
IGF in circulation (IGFBP3), transporting IGFs from the circulation to peripheral 
tissues (IGFBP1; 2; 4) or inhibiting IGF-IGF receptor interactions (IGFBP2; 4; 6) 
(reviewed in Jones and Clemmons 1995, Rajaram, Baylink et al. 1997). Most of the 
IGF1 in the circulation is bound in a ternary complex with the acid-labile subunit 
(ALS) to IGFBP3. GH action is directly required for the production of both, IGF1 
and ALS and indirectly for the production of IGFBP3 as its production is stimulated 
by IGF1 (reviewed in Cohick and Clemmons 1993). In LS, levels of IGF1, ALS 
and IGFBP3 are significantly reduced, indicating a disturbance in GH signaling 
through the GHR (Savage, Blum et al. 1993, Labarta, Gargosky et al. 1997). 
1.3. The growth hormone receptor 
The GHR is a 620-amino-acid transmembrane glycoprotein belonging to the family 
of class 1 cytokine receptors (reviewed in Waters 2015 and Brooks and Waters 
2010). The human GHR is encoded by 9 exons, numbered 2 – 10, which are located 
on chromosome 5 (Godowski, Leung et al. 1989). Exon 2 provides a signal peptide 
and the first part of the extracellular domain, which is mostly encoded by exon 3 – 
7. The transmembrane domain of the GHR is encoded by exon 8, whereas exon 9 
and 10 encode the cytoplasmic domain. In humans and pigs, proteolytic cleavage 
of a part of the extracellular domain releases the growth hormone binding protein 
(GHBP) into the circulation, which prolongs the half-life of GH by protecting it 
from excretion and degradation (reviewed in Baumann, Shaw et al. 1994). 
Furthermore, the GHBP competes with the extracellular domain of the GHR in 
binding circulating GH, thereby modulating the activity of GH (reviewed in Amit, 
Youdim et al. 2000).  
The GHR is present as a homodimer held together by strong interactions of the 
transmembrane helices, providing dimerization even at an inactive state (Gent, Van 
II. REVIEW OF THE LITERATURE     4 
Kerkhof et al. 2002). The dimerization of a GHR with a different cytokine receptor 
partner seems to be prevented by stereological hindrance of extracellular domains 
other than GHR (Lichanska and Waters 2008). The two distinct GHRs contain the 
same hormone-binding sites, but binding sites of GH are placed asymmetrically 
(Waters 2015). Binding of GH to the binding sites leads to positional readjustments 
of the extracellular domains involving rotation of the receptor molecules (Poger and 
Mark 2010). These conformational changes of the extracellular domain are 
transmitted via the transmembrane domain, switching to a crossover state, 
realigning catalytic subunits of the intracellular domain (Brooks and Waters 2010). 
Close to the cell membrane, the intracellular domain of the GHR contains the 
proline-rich box 1 motif – a common element of class 1 cytokine receptors – which 
binds the Janus kinase 2 (JAK2) (Tanner, Chen et al. 1995). The rotation of the 
GHR leads to a reorientation of the two box 1 motif-bound JAK2 molecules, 
increasing the distance between both, inducing the active state of JAK2 (Brooks, 
Abankwa et al. 2009). Basal JAK2 activity is inhibited by its own pseudokinase 
domain, holding the catalytic domain in an inactive state  (Saharinen, Vihinen et al. 
2003). Therefore, JAK2 activation requires the release of the tyrosine kinase from 
the pseudokinase domain. Waters et al hypothesized, that the pseudokinase domain 
of one inhibits the kinase domain of the other JAK2 (Waters 2015). The 
conformational changes, which increase the distance between the two box 1 motifs 
therefore remove the pseudokinase domain, bring the kinase domain into 
orientation and initiate the trans-activation of the JAK2 by each other (Brooks, Dai 
et al. 2014). Activated JAK2 proteins phosphorylate tyrosine residues of the 
cytoplasmic domain of the GHR forming binding sites for proteins containing 
phosphotyrosine binding domains (Herrington and Carter-Su 2001) such as the 
major substrate of GH action, the signal transducer and activator of transcription 5 
(STAT5), which contains the src homology domain 2 (SH2) (Rawlings, Rosler et 
al. 2004). The SH2 domain of STAT5 interacts with the activated binding site of 
the cytoplasmic GHR domain, enabling the tyrosine phosphorylation of STAT5 by 
JAK2 (Ihle 1996). The SH2 domain also mediates the dimerization of two STAT5 
proteins, what is hypothesized to trigger the dissociation from the complex with the 
GHR (Ihle 1996). Thereafter, the STAT5 dimer translocates to the nucleus and 
activates the transcription of target genes, such as IGF1 (Herrington, Smit et al. 
2000). An overview of the activation of the GHR is provided in Figure 1. 
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Figure 1. Activation of the growth hormone receptor. Binding sites on the GH 
are placed asymmetrically. Therefore, binding leads to rotation of the extracellular 
domain (1) of the GHR. These conformational changes are transmitted by the 
transmembrane domain (2) increasing the distance between the two box 1 motifs, 
allowing the catalytic activity of the JAK2 molecules at the intracellular domain 
(3). This leads to phosphorylation of tyrosine residues, forming a binding site for 
the phosphorylation of SH2-containing proteins as STAT5. The dimerization of two 
STAT5 molecules is provided by SH2 interaction, allowing the translocation to the 
nucleus and target gene transcription (4). (adapted from Brooks and Waters 2010). 
2. Pathophysiology of the Laron syndrome 
As mentioned, dwarfism in patients with LS cannot be due to reduced levels of GH 
as those are highly elevated. In fact, LS patients suffer from growth hormone 
receptor deficiency (GHRD), as liver samples derived from LS patients showed no 
binding capacity of human GH (Eshet, Laron et al. 1984). Under physiological 
conditions, GHR signaling - after activation by GH - induces the production of 
IGF1, IGFBP3 (Savage, Blum et al. 1993) and ALS (Labarta, Gargosky et al. 1997). 
IGF1 provides a negative feedback loop, decreasing the production of GH by the 
pituitary gland (reviewed in Brooks and Waters 2010). As GH signaling is 
diminished in LS patients, decreased levels of IGF1, IGFBP3, ALS and high levels 
of circulating GH are main characteristics of LS, which is commonly used 
synonymous to GHRD (Laron 2004). 
GHRD is an autosomal recessive hereditary disorder. Most mutations leading to 
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GHRD appear in the region encoding the extracellular, hormone binding domain of 
the GHR (Rosenfeld, Rosenbloom et al. 1994). The first cohort of LS patients was 
described by Zvi Laron (Laron, Pertzelan et al. 1968) and is referred to as the Israeli 
cohort, as most affected patients derived from the Middle-East. Many patients from 
this cohort descent from consanguineous families with different mutations of the 
GHR gene (reviewed in Laron 2004). Just as the mutations, the phenotype of LS 
patients from the Israeli cohort shows a high diversity (reviewed in Laron and 
Kopchick 2011).  
A more homogeneous cohort of LS patients was found in Ecuador by Guevara-
Aguirre et al and is referred to as the Ecuadorian cohort (Guevara-Aguirre, 
Rosenbloom et al. 1993). In this consanguineous cohort, nearly all patients carry an 
E180 splice mutation that probably originated in the Mediterranean area 
(Rosenbloom and Guevara-Aguirre 1998) and was carried from Spain to South 
America by Jews fleeing from the Spanish inquisition (Gonçalves, Fridman et al. 
2014, reviewed in Laron, Kauli et al. 2017).  
Unique cases of LS patients have been described, where the mutation occurs in the 
region of the gene encoding the intracellular domain of the GHR (Milward, 
Metherell et al. 2004). When the box1 motive – the receptor binding domain for 
JAK2 – is preserved, JAK2 signaling appears, but STAT5 activation is diminished 
as its binding domain of the GHR is truncated. In contrast to LS patients affected 
by the common locations of GHR mutations, these patients have GHBP in the 
circulation. Nevertheless, the phenotype of these LS patients did not differ from the 
more common forms in the Israeli and Ecuadorian cohorts regarding short stature, 
elevated GH whilst decreased IGF1 levels (Laron, Klinger et al. 1993, Milward, 
Metherell et al. 2004). 
While both cohorts show similarities in endocrine and auxologic hallmarks of the 
phenotype of LS, differences between the heterogeneous Israeli and more 
homogenous Ecuadorian cohort, regarding neurological findings and glucose 
metabolism are obvious (Kranzler, Rosenbloom et al. 1998, Guevara-Aguirre and 
Rosenbloom 2015) and a correlation between the differences in phenotype and 
specific mutations is hypothesized (Shevah, Kornreich et al. 2005). 
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3. Effects on metabolism 
As the GHR is expressed in various tissues, nearly the whole organism is affected 
by GHRD. Furthermore, GH and IGF1 have autocrine and paracrine mechanisms, 
which play an important role during the development of an organism (Varela-Nieto 
and Chowen 2005).  
3.1. Linear growth 
The birth weight of LS patients does not differ from their reference population. 
Growth retardation becomes apparent already during infancy and patients reach a 
height of 116 – 142 cm in males and 108 – 136 cm in females (Laron and Kopchick 
2011). No significant differences in growth patterns were observed between the 
Israeli and Ecuadorian cohorts of LS patients (Rosenbloom, Guevara Aguirre et al. 
1990). 
Regarding the endocrine regulation of linear growth, the maturation of the GH/IGF 
axis and its changing components and dependencies need to be considered. The 
maturation of the GH/IGF axis after birth is characterized by a shift in the relevance 
of specific growth factors (Hetz, Menzies et al. 2015). Intrauterine growth is 
stimulated by IGF2 and IGF1, and the production of both appears GH independent 
in this period of development (Baker, Liu et al. 1993), explaining why birthweights 
of LS patients remain unaffected. In contrast, postnatal growth is highly dependent 
on IGF1, whose production requires a stimulation by GH. The effects of GHRD on 
longitudinal growth cannot simply be explained by a lack of growth promotion by 
liver derived IGF1. In fact, the growth plate and endocrine actions are much more 
complex, including autocrine/paracrine interactions. The growth plate includes the 
cellular organization of specific layers whose dependence on GH and/or IGF1 
differs. In general, GH stimulates the differentiation of cells of the germinal layer, 
whereas IGF1 promotes the clonal expansion of cells in the proliferative layer, 
leading to longitudinal bone growth (Isaksson, Lindahl et al. 1987).  
Therefore, GHRD affects bone metabolism in a more complex manner, leading to 
a reduction in the width of the epiphyseal plate (reviewed in List, Sackmann-Sala 
et al. 2011), which is due to reduced proliferation of chondrocytes in the germinal 
layer (Wang, Zhou et al. 2004). Furthermore, bone mineral density is discussed to 
be reduced in LS patients, highlighting the effect of growth promoters on mineral 
homeostasis and skeletal health even after the termination of longitudinal bone 
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growth (reviewed in Laron and Kopchick 2011). 
3.2. Lack of GH action results in severe obesity 
GH is a potent regulator of lipid metabolism (reviewed in Vijayakumar, 
Novosyadlyy et al. 2010).  
The mass of adipose tissue is strongly and negatively correlated with GH levels 
(reviewed in Laron and Kopchick 2011), as GH provides lipolytic action by 
stimulating the efflux of free fatty acids from adipose tissues by an activation of the 
adipose tissue hormone-sensitive lipase (HSL). Furthermore, GH functions as an 
antagonist to insulin action on adipose tissues. It reduces glucose uptake by a 
downregulation of glucose transporters (Tai, Liao et al. 1990). 
Taking these manifold lipolytic actions provided by GH into account, it appears 
obvious that GHRD must increase the amount of adipose tissues in affected 
patients. Indeed, severe obesity starting at early childhood and increasing with age 
is a common characteristic in human LS patients (reviewed in Laron and Kopchick 
2011). Investigations on LS patients revealed that the increasing obesity is not due 
to an increased caloric intake. The most promising explanation for the increasing 
obesity may be provided by the change in lipid concentration observed in LS 
patients. High levels of fasting triglycerides, cholesterol and lipoprotein were 
assessed for adult patients of both cohorts (Laron and Karmon 2010, reviewed in 
Guevara-Aguirre, Rosenbloom et al. 2015). An increase of adipose levels from 
childhood towards the high levels in adulthood, may indicate a disturbance in 
adipocyte lipid turnover leading to the increase in adipose tissues. 
The function of adipose tissue includes more than simple energy storage, when 
taking its endocrine functions into consideration. Especially adipokines – such as 
leptin and adiponectin – have major endocrine actions (reviewed in Trujillo and 
Scherer 2006). Obesity is commonly associated with an increase of serum leptin 
levels, as seen in LS patients (Laron, Silbergeld et al. 1998). Leptin is a protein 
“signaling” the amount of adipose tissues and controlling energy intake and 
expenditure on hypothalamic level (reviewed in Jéquier 2002). Obesity induces a 
state of leptin resistance on hypothalamic level (El-Haschimi, Pierroz et al. 2000), 
as leptin induced weight loss is becoming diminished. When LS patients were 
compared to body mass index matched control relatives, a significant decrease in 
leptin levels was calculated (Guevara-Aguirre, Rosenbloom et al. 2015), allowing 
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to speculate that the obesity in LS patients is not associated with a developing leptin 
resistance. Adiponectin is known to decrease serum glucose and lipid levels by 
enhancing energy uptake and metabolism in muscles and reducing glucose 
secretion by the liver and increasing insulin sensitivity. While adiponectin levels 
are normally negatively correlated with obesity (Ryan, Berman et al. 2003), levels 
were constantly elevated in LS patients (Laron, Ginsberg et al. 2007).  
3.3. Glucose homeostasis 
Hypoglycemia is one of the first obvious symptoms of infants with LS – even with 
potential clinical complications - before growth retardation becomes obvious. Zvi 
Laron (Laron and Kopchick 2011) noted “The parents of the first encountered 
patients (Laron, Pertzelan et al. 1966) related that from early age, the children 
wake up at night asking for sweetened drinks. Not being served or when breakfast 
was delayed, they sweated profusely and were subject to loss of consciousness.”  
Interestingly, glucose levels of LS patients normalize when growing older. The 
investigation of underlying mechanisms focused on insulin homeostasis and 
responsiveness and revealed striking differences between the Israeli and 
Ecuadorian cohorts. 
Laron et al (Laron, Avitzur et al. 1995) observed high levels of insulin accompanied 
with the low levels of fasting glucose in young LS patients. The high levels of 
insulin – and results from HOMA-IR (Homeostatic Model Assessment for Insulin 
Resistance) values – indicate insulin resistance even when glucose values were low 
(reviewed in Laron and Kopchick 2011). GH is known to provide stimulatory 
effects on hepatic gluconeogenesis and to antagonize insulin signaling in the liver 
(reviewed in Vijayakumar, Novosyadlyy et al. 2010). The lack of these effects of 
GH may explain the hypoglycemia as seen in LS patients. The relation of glucose 
to insulin changed with age, leading to low levels of insulin and high levels of 
glucose in adulthood, suggesting an exhausting of pancreatic beta cells in face of 
developing insulin resistance. Glucose intolerance, insulinopenia and even cases of 
diabetes mellitus requiring insulin replacement therapy were reported for LS 
patients from the Israeli cohort (Laron, Avitzur et al. 1997). 
Contrary development of carbohydrate metabolism is reported for LS from the 
Ecuadorian cohort. As mentioned earlier, juvenile hypoglycemia and transient 
changes of glucose levels reaching adulthood are a common symptom for all LS 
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patients. But, Guevara-Aguirre et al  found patients from the Ecuadorian cohort 
being more insulin sensitive and no case of diabetes mellitus has been reported 
(Guevara-Aguirre and Rosenbloom 2015). This finding becomes even more 
astonishing, having the high degree of obesity in mind – which both cohorts have 
in common. Unfortunately, the differences in insulin sensitivity between the Israeli 
and Ecuadorian cohorts cannot be sufficiently explained by now (Guevara-Aguirre 
and Rosenbloom 2015). Differences due to the numerous mutations leading to 
GHRD in the Israeli cohort or different food supply and culture cannot be excluded. 
3.4. Protective effects of GHRD 
Insights from the Ecuadorian cohort of LS patients revealed a reduced incidence of 
cancer and diabetes. The same observation regarding cancer has been gained in the 
Israeli cohort. 
The incidence of cancer was estimated by a comparison of causes of death in LS 
patients to their relatives. In the Ecuadorian cohort, the history of 53 dead LS 
patients was compared to 1606 unaffected relatives. Cancer was the cause of death 
in 20% of relatives, whereas no case of cancer was reported in LS patients 
(Guevara-Aguirre, Balasubramanian et al. 2011). For a survey in the Israeli cohort, 
222 LS patients were compared to 338 unaffected relatives, gaining a similar result 
as from Ecuador: no LS patients died from cancer, whereas 9 to 24% of their 
relatives had a history of malignancies (Shevah and Laron 2007).  
The involvement of IGF1 in the development of malignancies is a proven fact 
(reviewed in Pollak, Schernhammer et al. 2004). Its proliferative and antiapoptotic 
effects are putatively involved in cancer development. Furthermore, high levels of 
circulating IGF1 are commonly associated with a higher incidence of cancer 
(reviewed in Calle and Kaaks 2004). The conclusion that the lower IGF1 levels in 
LS patients lower the risk of cancer is obvious.  
Besides the antiapoptotic effects of IGF1, a correlation between IGF1 signaling and 
increasing DNA damage was suggested by Guevara et al (Guevara-Aguirre, 
Balasubramanian et al. 2011). In a profound investigation, human mammary 
epithelial cells were incubated with serum derived from LS patients or their 
relatives. Just as expected, cells incubated with serum from GHR deficient patients 
showed fewer DNA brakes after treatment with H2O2. To evaluate the protective 
effects provided by GHRD serum, the expression rate of particular genes regulating 
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growth was evaluated. This analysis revealed a decreased expression of the 
mechanistic target of rapamycin (mTOR). The use of rapamycin in 
chemotherapeutic treatment of cancer draw the interest towards the target of 
rapamycin actions (reviewed in Sabatini 2017). Investigations revealed two protein 
kinase complexes – mTORC1 and mTORC2. mTORC1 contains the component 
raptor (regulatory protein associated with mTOR) and is inhibited by rapamycin, 
whereas mTORC2 is insensitive to rapamycin treatment as it contains rictor 
(rapamycin insensitive companion of mTOR) (reviewed in Saxton and Sabatini 
2017). The mTOR complexes act as a link between the availability of nutrients and 
the regulation of anabolic or catabolic processes on the cellular level. Energy intake 
increases the availability of glucose in the blood stream and uptake by cells. This 
input leads to an activation of mTORC1, which induces the production of proteins, 
lipids and nucleotides, providing cell growth. mTORC2 is affected by insulin 
signaling and implicated in the regulation of ion transport, apoptosis, glucose 
metabolism, cell migration and cytoskeleton rearrangement (reviewed in Oh and 
Jacinto 2011). A chronic activation of mTORC1 – as seen in over-feeding of 
Western diet – results in inhibition of insulin receptor (INSR) signaling, 
contributing to an onset of diabetic states (reviewed in Zoncu, Efeyan et al. 2011). 
On the other hand, reduced activity of mTOR1 is known to increase life-expectancy 
in model organisms such as Caenorhabditis elegans and Drosophila melanogaster 
(Sharp, Curiel et al. 2013). To distinguish between the activity of mTORC1 or 
mTORC2, downstream signal transducers specific for each complex were 
investigated. Just as expected, Guevara et al  revealed a decreased expression of 
protein S6 kinase (S6K) – a key element of mTORC1 - in cells incubated with 
serum derived from LS patients (Guevara-Aguirre, Balasubramanian et al. 2011).  
Unfortunately, no sufficient data for the life-expectancy of LS patients is available, 
as many cases are spread world-wide (Laron and Kopchick 2011) and 
socioeconomic consequences leading to high proportions of non-age related causes 
of death, such as alcohol toxicity, liver cirrhosis, convulsive disorders or accidents 
(Guevara-Aguirre, Balasubramanian et al. 2011). Nevertheless, an involvement of 
decreased mTOR signaling and protective effects associated with a lower activity 
of growth promotion providing protective effects was supposed and genetically 
engineered animal models were established for further investigations (Zhou, Xu et 
al. 1997). 
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4. Treatment of Laron syndrome 
Laron syndrome occurs due to a disturbance in the growth axis involving GH and 
IGF1. A substitution of GH would not be sufficient, as no rise in serum IGF1 could 
be observed (Laron, Pertzelan et al. 1971) since the defect leading to LS affects the 
GHR. Since 1990, recombinant biosynthetic IGF1 is used as treatment for LS 
beginning at infancy (reviewed in Laron and Kopchick 2011). A long-term 
treatment starting at early ages is seen most sufficient, as the growth promoting 
effect of IGF1 administration is greater in young children (Laron 1993). 
Unfortunately, the half-life of exogenous IGF1 is reduced in LS patients compared 
to healthy subjects (Laron 1993). As mentioned earlier, most IGF1 in circulation is 
bound by IGFBP3 and ALS, which prolong the half-life of IGF1 by preventing its 
excretion and degradation. The production of IGFBP3 and ALS are both depending 
on GH signaling, which is diminished in GHRD, leading to low levels of both, 
decreasing the half-life of exogenous IGF1 (Rosenbloom 2016). Therefore, the 
administration of IGF1 has to be performed on a daily base until the final height is 
reached and cartilage epiphyses are closed. The long-term treatment of children 
with exogenous IGF1 leads to an increase in growth velocity, reduction in body fat 
and modifies the craniofacies (Carel, Chaussain et al. 1996). Adverse effects of 
IGF1 treatment are reported, involving hypoglycemia, headache, intracranial 
hypertension, swelling of lymph nodes and hyperandrogenism (reviewed in Laron 
and Kauli 2016). Luckily, most adverse effects are just due to over dosage or 
administration without food. The treatment of LS patients with exogenous IGF1 
beginning at childhood leads to an increase of growth velocity, but patients still do 
not reach the estimated parental target height, as the direct effects of GH on the 
growth plate cannot be restored (Rosenbloom 2016). A beneficial effect of IGF1 
treatment was observed in adult LS patients due to metabolic effects, for example 
reducing cholesterol levels and enhancing renal functions (Laron and Klinger 
1994). Unfortunately, these positive effects in adults reverse once the 
administration of IGF1 is stopped. 
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5. Animal models for GH-deficiency and Laron syndrome 
The Laron Syndrome provides a unique opportunity to study the various effects of 
GH signaling regarding growth and metabolism in humans. Furthermore, the 
possible protective effects on malignancies associated with diminished GH 
signaling in GHRD draw the interest toward further investigations of this syndrome. 
The study of human patients with LS rises several difficulties, as human cases are 
very rare and spread world-wide. The variety of mutations, especially in the Israeli 
cohort, and environmental factors complicate the comparability of findings in 
human patients and accentuate the need for suitable animal models. 
5.1. The sex-linked dwarf chicken 
The aim to produce smaller breeding hens in the poultry industry without affecting 
the size broilers led to the establishment of a sex-linked mutation leading to 
dwarfism (SLD) in several strains of breeding hens in the mid of the 20th century 
(Mérat 1984). The recessive dw mutation of the GHR gene on the Z–chromosome 
(Agarwal, Cogburn et al. 1994, Boegheim, Leegwater et al. 2017) leads to a 30-
40% reduction of body weight in hens, whereas heterozygosity does not affect male 
chicken. It was argued, that SLD chicken exhibit a form of inherited GH resistance 
due to GHR dysfunction, as no detectable GH binding activity, reduced levels of 
IGF1 and adiposity were observed (reviewed in Hull and Harvey 1999). 
Nevertheless, the SLD chicken never prevailed as a widely used model for LS due 
to the large taxonomic difference between birds and mammals. 
5.2. Guinea pigs 
Guinea pigs seem to be resistant to the growth promoting effects of GH. Studies 
with extracts derived from guinea pig pituitary glands revealed a growth promoting 
effect of hypophysectomized rats, whereas no effect on guinea pigs themselves was 
observed (reviewed in Hull and Harvey 1999). While a growth impairment in 
guinea pigs was suspected, it was revealed that their growth occurs independent 
from GH action. In contrast to other mammals, the IGF1 production in guinea pigs 
appears independent from GH (reviewed in Keightley and Fuller 1996), limiting its 
potential as a sufficient animal model for LS. 
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5.3. The miniature Bos indicus cattle 
The study of Liu et al (Liu, Boyd et al. 1999) investigated the underlying defects of 
a line of miniature Bos indicus cattle. As the small size and high levels of circulating 
GH, whilst IGF1 levels were reduced pointed towards a defect similar to Laron 
syndrome, the endocrine conditions were investigated in detail. It was shown, that 
the condition was inherited as a recessive gene and exogenous GH administration 
did not restore the levels of circulating IGF1. Nevertheless, a genetic defect of the 
GHR gene - as essential for LS - was not found in those miniature cattle. The cause 
of this phenotype is a mutation of the GH gene affecting the GHR binding domain 
and thus leading to reduced binding of GH to its receptor (reviewed in Boegheim, 
Leegwater et al. 2017), decreased expression of IGF1, and reduced growth velocity 
of affected animals. Probability due to taxonomic and pathophysiologic differences, 
the miniature Bos indicus cattle has not been established as a proper animal model 
for LS. 
5.4. The Laron / Ghr KO mouse 
The first animal model for LS stablished by targeted mutation of the Ghr gene was 
the Laron mouse / Ghr KO mouse by Zhou et al (Zhou, Xu et al. 1997) at the lab 
of John Kopchick in 1997. By targeting exon 4 of the murine Ghr gene, the 
expression of both, GHR and GHBP was eliminated. The resulting GHR/BP KO 
mouse has been used in several GH-related studies (reviewed in List, Sackmann-
Sala et al. 2011). In brief, the Ghr KO mouse mimics several hallmarks of the 
human phenotype of LS. As GH signaling is abolished, low levels of circulating 
IGF1 and increased levels of GH in circulation have been observed in all studies 
(reviewed in List, Sackmann-Sala et al. 2011). The lack of GH-related growth 
promotion leads to the characteristic dwarf phenotype due to post-natal growth 
failure, whereas birth weights remain unaffected. Coschigano et al observed 
improved longevity in the Ghr KO mouse, as speculated from the human phenotype 
and other GH insensitive mice models (Coschigano, Clemmons et al. 2000). A 
connection between improved insulin sensitivity and pro-aging effects was 
suggested. In fact, young Ghr KO mice have been found to be more insulin sensitive 
leading to hypoglycemia as in human patients of LS accompanied with 
hyperinsulinemia (Liu, Coschigano et al. 2004). The transient changes from hypo- 
to normoglycemia as seen in human LS patients also occurred in the Ghr KO 
mouse, but in contrast to finings of Laron et al (Laron, Avitzur et al. 1995), insulin 
II. REVIEW OF THE LITERATURE     15 
sensitivity of Ghr KO mice remains increased their entire life span, associated with 
decreased levels of fasting insulin. The improved insulin sensitivity and longevity 
gets even more impressive since the Ghr KO mouse is reported to be obese. Several 
studies focused on the body composition of the Ghr KO mouse, since severe obesity 
is reported to be a major characteristic of the human LS. While studies consistently 
showed, that the Ghr KO mouse has an absolute reduction in lean mass, the relative 
reduction is proportional to the growth retardation (reviewed in List, Sackmann-
Sala et al. 2011). In contrast, an increase of percentage of body fat has been reported 
for the Ghr KO mouse. Whereas in human patients of LS, females are reported to 
have greater percentage of body fat than males, female Ghr KO mice showed lower 
values than males (Berryman, List et al. 2010). The authors avoid to call this 
phenotype a pronounced obesity, as the absolute fat mass of the dwarf sized Ghr 
KO mice does not differ from controls. Furthermore, the accumulation of fat mass 
in particular depots is dramatically changed in the Ghr KO mice, as a 
disproportional enlargement of subcutaneous fat has been observed, highlighting 
tissue-specific effects of GHRD.  
The metabolic changes in the Ghr KO mouse are often compared to a state of caloric 
restriction (CR) (reviewed in List, Sackmann-Sala et al. 2011). As CR is associated 
with increased life expectancy and the prevention of cancer (Longo and Fontana 
2010), similarities between Ghr KO mice and control animal raised under CR are 
interpreted as beneficial effects of GHRD. Similarities are further surprising, as Ghr 
KO mice show a high percentage of body fat, but Longo et al hypothesized, that the 
reduced levels of circulating IGF1 simulate a state of CR (Longo and Finch 2003) 
even when Ghr KO mice consume relatively more energy than control animals 
(reviewed in List, Sackmann-Sala et al. 2011). While it has been shown that CR 
increases the life-span of Ames dwarf mice (Bartke, Wright et al. 2001) - with 
diminished GH, thyroid stimulating hormone (TSH) and prolactin production – no 
increase in life expectancy was observed in Ghr KO mice under CR (Bonkowski, 
Rocha et al. 2006). It has been suggested, that the positive effects of GH deficiency 
combined with CR increase the life-span of Ames dwarf mice, while CR was not 
sufficient to further increase the already improved insulin sensitivity in Ghr KO 
mice (Bonkowski, Rocha et al. 2006, reviewed in List, Sackmann-Sala et al. 2011). 
Furthermore, no differences in specific gene expression in the liver due to CR have 
been observed in Ghr KO mice, while CR significantly altered the gene expression 
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in control animals under CR (Miller, Chang et al. 2002). It is further known, that 
CR results in a reduced activity of mTORC1, which contributes to the development 
of cancer (Longo and Fontana 2010). In line with an expected reduced activity of 
mTORC1 in Ghr KO mice, Dominick et al. showed a reduced activity of mTORC1 
while mTORC2 activity was enhanced according to the investigation of 
downstream substrates (Dominick, Berryman et al. 2015).  
Besides these positive effects of GHRD on the phenotype of the Ghr KO mouse, a 
reduced fertility was observed in several studies (reviewed in List, Sackmann-Sala 
et al. 2011). While in human LS patients, no fertility problems besides a delay in 
puberty and hypogenitalism have been reported and affected patients can reproduce 
(reviewed in Laron and Kopchick 2011), female Ghr KO mice are reported as 
subfertile, producing fewer pups due to a reduced ovulation rate and an increased 
postnatal mortality has been observed (Zhou, Xu et al. 1997, Danilovich, Wernsing 
et al. 1999).  
It is undeniable that the Ghr KO mouse provided tremendous insight on the GH/IGF 
axis and the LS in particular. Nevertheless, mouse models have several limitations 
in common representing the phenotype of human disorders resulting from their 
small size, short life expectancy and physiological differences from humans. 
Regarding the LS and overall investigations of the GH/IGF1 axis, the different 
timing of maturation of the endocrine growth axis in mice and humans has to be 
considered. In contrast to humans, the maturation of the hypothalamic–pituitary–
adrenal axis (HPA axis) of rodents occurs in the postnatal period (Symonds, Sebert 
et al. 2009). To overcome this limitation, a large animal model which is not born in 
this “immature” state but with a fully mature HPA axis at birth occurred necessary.  
5.5. Wuzhishan minipigs with dominant-negative GHR 
The approach to overexpress a dominant-negative GHR to generate a minipig 
model for LS was followed by Li et al (Li, Li et al. 2015). The idea was, that the 
overexpression of a non-functional GHR under the control of the ubiquitously 
active CAG promoter might bind large amounts of circulating GH, reducing 
sufficient signaling by the still functional wild-type (WT) GHR. Indeed, the 
expression of the dominant-negative GHR was about 100-fold increased compared 
to the WT GHR and GH levels in circulation were elevated 9-fold in transgenic 
pigs. In contrast to findings in humans and mice, an increase in fasting blood 
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glucose levels was estimated analyzing pooled samples of animals aged one, five 
and 77 days. It remains unclear, why the values of the different age groups were 
pooled and age-dependent changes in metabolism were investigated. Furthermore, 
IGF1 levels in transgenic pigs were not reduced in a significant manner, suggesting 
residual signaling via the residual WT GHR, making its use as a proper animal 
model for LS questionable. 
5.6. The GHR deficient miniature pig 
Cui et al (Cui, Li et al. 2015) generated the first miniature pig model with a knock 
out of the GHR gene by applying the zinc finger nuclease technology targeting exon 
6. As expected, these GHR deficient pigs showed elevated GH levels in circulation, 
whereas IGF1 levels were decreased. Growth retardation became obvious after 
weaning, obesity was obvious by eyesight and high abundance of abdominal fat 
was observed at necropsy. Hypoglycemia has been described, but unfortunately the 
age of the corresponding pigs has not been clarified and a transiency as observed in 
human LS patients has not been estimated.  
Miniature pigs are a highly recommended animal models in research, but since they 
are already growth impaired it may be questioned if a GHR KO on this background 
resembles all pathophysiological consequences of the human LS. Miniature pigs 
are dwarf breeds, characterised by “proportional dwarfism” of all body parts. As 
this type of dwarfism is seen to be associated with genetically caused dwarfism, 
such as IGF1 deficiency (Simianer and Köhn 2010), it has been speculated, that the 
selection for the dwarf phenotype led to an accumulation of alleles downregulating 
the GH/IGF pathway (Gärke, Ytournel et al. 2014). To maintain a pig population 
with undisturbed IGF1 function, we used the German landrace, since no selection 
for smaller body size occurred in this breed. 
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6. Methods for the genetic modification of pigs  
According to the from bench to bedside principle in translational medicine, 
genetically tailored large animal models are required to bridge gaps between basic 
research in genetically modified rodent models and human diseases and syndromes 
(reviewed in Aigner, Renner et al. 2010, Dmochewitz and Wolf 2015). The usage 
of pigs as a large animal model steadily increases as it models the human situation 
more accurately (Lunney 2007). Several techniques for engineering of the pig 
genome are available, but they differ in their efficiency (reviewed in Dmochewitz 
and Wolf 2015).  
6.1. Pronuclear DNA microinjection 
The first approach to generate transgenic pigs was to inject DNA directly into 
pronuclei of zygotes (Hammer, Pursel et al. 1985, Selden, Springman et al. 1985). 
Unfortunately, the efficiency of this method is quite low and the risk to generate 
transgenic animals with mosaicism occurs (reviewed in Dmochewitz and Wolf 
2015). As the integration of the injected DNA appears randomly, no target-site 
integration could be achieved, leading to different expression levels of the 
integrated transgene, as its expression can be influenced by effects of neighboring 
DNA (reviewed in Luo, Lin et al. 2012). 
6.2. Sperm-mediated gene transfer 
A further approach to increase the efficiency of gene transfer and to generate 
multigene transgenic animal models was the sperm-mediated gene transfer (SMGT) 
(Lavitrano, Busnelli et al. 2005). Using the intrinsic ability of sperm to take up 
exogenous DNA, a transfer into oocytes occurring during fertilization could be 
achieved (reviewed in Aigner, Renner et al. 2010). Nevertheless, just the same 
limitations as for DNA microinjections appear as no target-site directed gene 
transfer and no target knock-out of genes is possible (reviewed in Luo, Lin et al. 
2012). 
6.3. Lentiviral vectors 
Belonging to the family of Retroviridae, lentiviruses can transfer RNA into cells 
via their infection. Lentiviral RNA is further transcribed into DNA by the reverse 
transcriptase and integrated into the host genome and transmitted through the germ 
line to the founder animal´s offspring (reviewed in Aigner, Renner et al. 2010). A 
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major advantage of lentiviral vectors is, that the transduction can appear in non-
dividing cells, allowing the operator to reduce the risk of creating mosaicism in 
founder animals, when the integration appears in early embryo development 
(Pfeifer 2004). Limitations of lentiviral vectors occur, when larger inserts are 
transfected and furthermore, the possible case of multiple independent integration 
sites and their segregation in the founder animal´s offspring need to be considered 
(reviewed in Dmochewitz and Wolf 2015). 
6.4. SCNT from genetically modified cells 
As no porcine embryonic stem cells are available, the use of genetically modified 
somatic cells as donor cells for somatic cell nuclear transfer (SCNT) is a well-
established method to generate genetically modified pig strains (reviewed in 
Dmochewitz and Wolf 2015). A detailed protocol is provided in (Kurome, Kessler 
et al. 2015). A wide range of somatic cells, like porcine fetal, ear or kidney 
fibroblasts, or mesenchymal stem cells are used. Usually, gene constructs are 
combined with resistance cassettes against a specific antibiotic, to enable a selection 
process after transfection of the cells. In case of gene targeting, the target specific 
introduction of the vector has to be verified. The possibility to screen for success of 
the genetic modification prior to the production of embryos and embryo transfer is 
a major advantage of this method. To generate SCNT embryos, in vitro matured 
oocytes are enucleated and single donor cell is inserted into the zona pellucida. 
Oocyte cytoplasm and donor cell are then fused and activated, and the reconstructed 
embryos are transferred into recipient gilts (Besenfelder, Modl et al. 1997). 
6.5. Zinc finger nucleases 
For targeted engineering of the pig genome, customized nucleases are available, 
such as the zinc finger nuclease (ZFN), offering the advantage that this technology 
can be applied via the cytoplasmic injection into zygotes, without requiring somatic 
cell nuclear transfer (SCNT) (reviewed in Dmochewitz and Wolf 2015). ZFNs are 
composed of a pair of fusion protein, containing the DNA cleavage domain (FokI 
endonuclease) and a site specific DNA binding domain (reviewed in Luo, Lin et al. 
2012). The binding domain is composed as “fingers” made up of 30-amino-acids 
coordinated by a zinc atom contacting 3bps of target DNA (Porteus and Carroll 
2005). Each finger independently binds its target site. Therefore, the use of multiple 
fingers increases the specificity of target-site binding (Whitelaw, Sheets et al. 
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2016). ZFNs are used as pairs, binding the opposite DNA strands, as each binding 
domain is complexed with just one half of the dimeric endonuclease (Gaj, Gersbach 
et al. 2013). After the target-site binding, the endonuclease dimerization provides 
double stand breaks (DSBs) of the host DNA, inducing the cell´s intrinsic repair 
mechanisms such as non-homologous end-joining (NHEJ) or homology-directed 
repair (HDR) (Luo, Lin et al. 2012). The repair of DSBs by NHEJ contains the 
opportunity to generate mutations due to insertions or deletions, whereas a repair 
mechanism involving HDR enables the introduction of exogenous DNA, linked to 
templates homologous to host´s target region (Dmochewitz and Wolf 2015). The 
wide application of ZFNs increased the efficiency of gene targeting due to the site 
specific DNA binding domain, and allowed the site specific introduction of 
exogenous DNA. Nevertheless, their use is complicated as designing of specific 
DNA binding sites is time consuming and expensive (reviewed in Bogdanove and 
Voytas 2011). 
6.6. TALENs 
Just as ZFNs, transcription activator-like effector nucleases (TALENs) can be 
applied for target engineering of the pig genome. TAL effectors are known as 
virulence factors of the bacteria Xanthomonas as they mimic transcription factors 
of eukaryotic cells and thereby change the cell´s gene expression (Boch, Scholze et 
al. 2009). TAL effectors contain tandem amino acid repeats targeting promoter 
sequences of the host genome (Bogdanove and Voytas 2011). Target DNA binding 
can be achieved by generating artificial tandem repeats (Luo, Lin et al. 2012). TAL 
effectors can be equipped with the FokI restriction enzyme creating TAL effector 
nucleases (TALENs) (Dmochewitz and Wolf 2015). As FokI operates as a dimer, 
TALENS need to be designed as pairs, binding opposite DNA target sites to induce 
DSBs (Bogdanove and Voytas 2011). While the efficiency of TALENs is 
comparable with ZFNs, the architecture of TAL effectors as tandem repeats offers 
difficulties in designing new target binding sequences (Luo, Lin et al. 2012).  
6.7. CRISPR/Cas 
Derived from Streptococcus pyogenes, the clustered regularly interspaced short 
palindromic repeat (CRISPR)/Cas9 endonuclease technology has been successfully 
used to generate genetically tailored small animal and pig models (Hai, Teng et al. 
2014). In bacteria and archaea, the CRISPR/Cas system serves as a form of an 
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adaptive immune system. After infection by viruses or plasmids, short nucleic acid 
fragments are integrated as Spacer sequences in the host genome framed by a repeat 
motif, leading to the characteristic repeat – spacer – repeat architecture of the 
CRISPR sequence (reviewed in Gaj, Gersbach et al. 2013, Seruggia and Montoliu 
2014). The CRISPR locus is transcribed into CRISPR-derived RNAs (crRNAs) 
containing the spacer sequences of foreign nucleic acids. At a further infection, the 
foreign nucleic acids - referred to as protospacer sequence - can be detected by the 
crRNAs and destructed by the CRISPR-associated (Cas) endonucleases which form 
a complex with the guiding crRNA (reviewed in Wiedenheft, Sternberg et al. 2012). 
An illustration of the general function of the CRISPR/Cas system is provided in 
Figure 2. 
 Figure 2. General 
function of the 
CRISPR/Cas system as a 
prokaryotic adaptive 
immune system. Foreign 
nucleic acids (proto-
spacers) are acquired as 
spacers at the leader end 
of the host´s CRISPR 
array (1), characterized by 
the repetitive abundance 
of spacer and repeat 
sequences (indicated as 
grey boxes marked with 
“R”). Spacer sequences 
are transcribed as 
CRISPR – derived RNA 
(crRNA), providing a 
form of „spacer library“ 
(2). At a further infection 
with an already known 
pathogen, the complementary crRNA binds to the intruder’s protospacer domain 
close to the protospacer - associated motif (PAM) enabling the activity of Cas 
endonucleases (adapted from Bhaya, Davison et al. 2011). 
Three types of CRISPR/Cas systems are known in bacteria and archaea. Type I and 
III just show little differences in the synthesis of crRNA and in required Cas 
endonucleases (reviewed in Bhaya, Davison et al. 2011). To adapt the CRISPR/Cas 
system as a tool for genetic engineering, the CRISPR/Cas Type II is used as the 
Cas9 endonuclease can perform DSBs even in eukaryotic cells. Homologue to the 
target gene sequence (protospacer sequence), a single guiding RNA (sgRNA) is 
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designed by the fusion of the target crRNA and the so-called trans-activating 
crRNA (tracrRNA) which is necessary for the activity of the Cas9 endonoclease 
(reviewed in Seruggia and Montoliu 2014). When several different sgRNAs are 
applied, it is even possible to target multiple loci in a single model (Wang, Yang et 
al. 2013). Injection of the sgRNA and RNA encoding for the Cas9 endonuclease in 
for example zygotes induces the assembling of the two components (Hai, Teng et 
al. 2014). DSBs are achieved by activity of two distinct Cas9 domains, where the 
Cas9 HNH nuclease domain cleaves the complementary and the Cas9 RuvC-like 
nuclease domain cleaves the non-complementary DNA strand (Jinek, Chylinski et 
al. 2012). It has to be noted, that the activity of the Cas9 endonuclease requires a 
protospacer-associated motif (PAM) (Anders, Niewoehner et al. 2014) close to the 
target protospacer sequence, wherein the DSB is induced (reviewed in Bhaya, 
Davison et al. 2011). The use of the CRISPR/Cas9 system as a tool for genetic 
engineering is illustrated in Figure 3. Targeted mutations are achieved by NHEJ or 
the introduction of genetic information by HDR, inserting donor templates 
containing homologous arms (reviewed in Dmochewitz and Wolf 2015).  
Figure 3. The CRISPR/Cas9 system as a 
tool for genetic engineering. An artificial 
single sgRNA containing the linked 
crRNA and tracrRNA is designed 
complementary to the protospacer 
sequence of the target genome inducing the 
activity of the Cas9 endonuclease. Being a 
part of the Type II CRISPR/Cas system, to 
separate domains of the Cas9 endonuclease 
cleave the complementary and non-
complementary strand inducing a DSB 
(adapted from Jinek, Chylinski et al. 2012). 
In summary, the use of the CRISPR/Cas9 system emerged rapidly due to the ease 
of designing guiding RNAs in contrast to protein engineering required for ZFN and 
TALEN applications, making it an ideal tool for the generation of genetically 
tailored pig models (reviewed in Dmochewitz and Wolf 2015) as used in our study.  
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ABSTRACT 
Objective: Laron syndrome (LS) is a rare, autosomal recessive disorder in humans 
caused by loss-of-function mutations of the growth hormone receptor (GHR) gene. 
To establish a large animal model for LS, pigs with GHR knockout (KO) mutations 
were generated and characterized. 
Methods: CRISPR/Cas9 technology was applied to mutate exon 3 of the GHR gene 
in porcine zygotes. Two heterozygous founder sows with a 1-bp or 7-bp insertion 
in GHR exon 3 were obtained, and their heterozygous F1 offspring were 
intercrossed to produce GHR-KO, heterozygous GHR mutant, and wild-type pigs. 
Since the latter two groups were not significantly different in any parameter 
investigated, they were pooled as the GHR expressing control group. The 
characterization program included body and organ growth, body composition, 
endocrine and clinical-chemical parameters as well as signaling studies in liver 
tissue. 
Results: GHR-KO pigs lacked GHR and had markedly reduced serum insulin-like 
growth factor 1 (IGF1) levels and reduced IGF-binding protein 3 (IGFBP3) activity, 
but increased IGFBP2 levels. Serum GH concentrations were significantly elevated 
compared with control pigs. GHR-KO pigs had a normal birth weight. Growth 
retardation became significant at the age of five weeks. At the age of six months, 
the body weight of GHR-KO pigs was reduced by 60 % compared with controls. 
Most organ weights of GHR-KO pigs were reduced proportionally to body weight. 
However, the weights of liver, kidneys, and heart were disproportionately reduced, 
while the relative brain weight was almost doubled. GHR-KO pigs had a markedly 
increased percentage of total body fat relative to body weight and displayed 
transient juvenile hypoglycemia along with decreased serum triglyceride and 
cholesterol levels. Analysis of insulin receptor related signaling in the liver of adult 
fasted pigs revealed increased phosphorylation of IRS1 and PI3K. In agreement 
with the loss of GHR, phosphorylation of STAT5 was significantly reduced. In 
contrast, phosphorylation of JAK2 was significantly increased, possibly due to the 
increased serum leptin levels and increased hepatic leptin receptor expression and 
activation in GHR-KO pigs. In addition, increased mTOR phosphorylation was 
observed in GHR-KO liver samples, and phosphorylation studies of downstream 
substrates suggested the activation of mainly mTOR complex 2.  
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Conclusion: GHR-KO pigs resemble the pathophysiology of LS and are an 
interesting model for mechanistic studies and treatment trials. 
 
Highlights: 
Growth hormone receptor (GHR)-deficient pigs reveal postnatal growth 
retardation, disproportionate organ growth and an increased total body fat content, 
associated with markedly reduced IGF1 and IGFBP3 levels, but increased IGFBP2 
activity. 
Transient juvenile hypoglycemia in the presence of normal insulin levels and 
increased expression and phosphorylation of IRS1 in liver of adult GHR-deficient 
pigs suggest increased insulin sensitivity. 
Increased phosphorylation of JAK2 in liver of GHR-deficient pigs may be 
explained by increased serum leptin levels and increased expression and 
phosphorylation of hepatic LEPR. 
Abbreviations: 
4EBP1, eukaryotic initiation factor 4E binding protein 1; aa, amino acid; AKT, 
serine-threonine protein kinase; AMPK, AMP-activated protein kinase; 
CRISPR/Cas, clustered regularly interspaced short palindromic repeats/CRISPR-
associated; DAB, 3,3′-diaminobenzidine; DXA, dual-energy X-ray absorptiometry; 
eIF4E, eukaryotic translation initiation factor 4E; ELISA, enzyme-linked 
immunosorbent assay; GH, growth hormone; GHR, growth hormone receptor; 
GSK3B, glycogen synthase 3 beta; HDL, high-density lipoprotein; HOMA, 
homeostatic model assessment; HSL, hormone-sensitive lipase; IGF1, insulin-like 
growth factor 1; IGFBP, IGF-binding protein; IgG, immunoglobulin G; INSR, 
insulin receptor; IRS1, insulin receptor substrate 1; JAK2, Janus kinase 2; LS, 
Laron syndrome; LSM, least squares mean; LDL, low-density lipoprotein; LEPR, 
leptin receptor; LPL, lipoprotein lipase; MAPK, mitogen-activated protein kinase; 
MRI, magnetic resonance imaging; mTOR, mechanistic target of rapamycin; 
mTORC, mTOR complex; PCR, polymerase chain reaction; PI3K, 
phosphoinositide 3 kinase; PPARG, peroxisome proliferator-activated receptor 
gamma; RIA, radioimmunoassay; S6K, protein S6 kinase 1; SE, standard error; 
sgRNA, single guide RNA; STAT, signal transducer and activator of transcription; 
TBS, Tris-buffered saline.   
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1. INTRODUCTION 
Laron syndrome (LS) is a rare autosomal recessive hereditary disorder caused by 
loss-of-function mutations in the growth hormone receptor (GHR) gene 
(https://www.omim.org/entry/600946), initially described as a syndrome of 
primary growth hormone (GH) resistance or insensitivity (1; reviewed in 2, 3). As 
a consequence, LS patients have low levels of insulin-like growth factor 1 (IGF1) 
and – due to the lack of feedback inhibition of GH secretion – high levels of GH 
[3]. A few hundred cases of LS have been reported world-wide, caused by a variety 
of GHR mutations (reviewed in 4). Among them is an isolated more homogeneous 
population of GHR deficient patients in Ecuador with only two distinct mutations 
of the GHR gene [5-7]. 
The main clinical feature is short stature. In addition, LS patients may exhibit 
reduced muscle strength and endurance, hypoglycemia in infancy, delayed puberty, 
obesity, and distinct facial features, including a protruding forehead, sunken bridge 
of the nose, and blue sclerae (reviewed in 3, 8). The standard treatment of LS is 
long-term application of recombinant IGF1, which increases growth velocity and 
improves adult height, but it may lead to a spectrum of side effects, in particular 
hypoglycemia (9, 10; reviewed in 11). 
A particularly interesting observation in LS patients is their reduced incidence of 
malignancies (12, 13; reviewed in 8). In addition, LS patients from the cohort in 
Ecuador have been shown to be protected against the development of type 2 
diabetes despite severe obesity [7].  
Although mechanistic studies have been performed in cell lines derived from LS 
patients and healthy controls [7, 14], animal models are of pivotal importance for 
understanding the pathophysiology of LS in vivo. In particular, GHR-deficient mice 
[15] have provided new insights into the consequences of GH insensitivity for body 
and organ growth, body composition, endocrine and metabolic functions, and 
reproduction, as well as aging and life expectancy (reviewed in 16). More recently, 
inducible/tissue-specific Ghr knockout (KO) mouse models have helped to define 
the specific roles of GHR in liver, muscle and adipose tissue and revealed 
interesting differences compared with constitutive Ghr KO mice [17, 18]. However, 
due to their small size, short life expectancy and physiological differences 
compared with humans, findings from mouse models may be difficult to extrapolate 
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to the clinical situation of LS patients. In general, genetically tailored pig models 
are useful to bridge the gap between proof-of-concept studies in rodent models and 
clinical studies in patients (reviewed in 19, 20). Thus, we have developed a GHR-
deficient (GHR-KO) pig model and show that it resembles important aspects of LS 
pathophysiology and reveals altered activation of signaling cascades in the liver. 
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2. MATERIALS AND METHODS 
2.1. Generation of GHR mutant pigs using CRISPR/Cas 
All animal procedures in this study were approved by the responsible animal 
welfare authority (Regierung von Oberbayern; permission 55.2-1-54-2532-70-12) 
and performed according to the German Animal Welfare Act and Directive 
2010/63/EU on the protection of animals used for scientific purposes. 
For CRISPR/Cas-assisted GHR gene disruption using a single guide RNA (sgRNA) 
specific for exon 3 sequence 5’-TTCATGCCACTGGACAGATG-3’, a 
corresponding oligonucleotide was cloned into the pEX-A-U6-gRNA vector as 
described previously [21]. Cas9 mRNA and sgRNA were in vitro-transcribed using 
the Ambion Maxiscript SP6 kit (Thermo Fisher Scientific).  
Porcine zygotes (German landrace background) were produced in vitro as described 
previously [22], and Cas9 mRNA (50 ng/µL) and sgRNA (100 ng/µL) was injected 
into their cytoplasm 8.5-9.5 hours after in vitro fertilization. Recipient gilts were 
synchronized in the estrous cycle by oral administration of 4 mL Altrenogest 
(Regumate®; MSD Animal Health) for 15 days, followed by intramuscular injection 
of 750 IU ECG (Intergonan®; MSD Animal Health) and 750 IU HCG (Ovogest®; 
MSD Animal Health) after an additional 24 and 104 hours, respectively. Embryo 
transfer was performed laparoscopically into one oviduct [23, 24]. Pregnancy was 
confirmed by ultrasonographic examination first on day 21 and again 4-6 weeks 
later.  
Genomic DNA was isolated from tail tips of piglets using the Wizard DNA 
Extraction Kit (Promega). GHR mutations were detected by sequencing a GHR 
exon 3 PCR product obtained using primers GHR_Fw 5’-acc gct ctg aag ctg tga 
cc-3’ and GHR_Rv 5’-cac cct cag ata ctc tca tgc-3’. Based on the detected 
mutations, an XcmI restriction fragment length polymorphism assay was 
established, yielding fragments of 203 bp and 441 bp for wild-type GHR and a 
single fragment of 644 bp for the mutated GHR sequence. 
Two female founder animals with different frameshift mutations were mated with 
wild-type boars to generate heterozygous F1 offspring. Heterozygous offspring of 
the same founder were intercrossed to obtain homozygous animals (GHR-KO) with 
the respective GHR mutations. The resulting pedigrees are shown in Suppl. Fig. 1. 
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2.2. Ligand immunostaining of porcine GHR 
Liver and kidney tissue of GHR-KO and control pigs was fixed overnight in 4 % 
formalin and routinely embedded in paraffin. Paraffin sections were dewaxed, and 
endogenous peroxidase and biotin were blocked with 1 % H2O2 in Tris-buffered 
saline (TBS) for 15 min and by using the avidin/biotin blocking kit (no. SP-2001; 
Vector Laboratories), respectively. After blocking with 0.5 % fish gelatin for 30 
min, the slides were incubated in 0.5 µg/mL recombinant rat GH (no. 16343667, 
ImmunoTools) in 0.2 % fish gelatin solution overnight at 4°C. They were then 
washed 3 times for 5 min in TBS and incubated in goat-anti rat GH polyclonal 
antibody solution (dilution 1:2,400, no. AF1566, R&D Systems) for 6 hours at room 
temperature. After 3 washing steps in TBS (10 min each), the slides were incubated 
in biotinylated rabbit-anti goat IgG solution (dilution 1:100, no. BA-5000, Vector 
Laboratories) for 1 hour at room temperature, washed 3 times for 10 min in TBS, 
and finally incubated with horseradish peroxidase-labelled avidin biotin complex 
for 30 min (no. PK-6100, VECTASTAIN Elite ABC-Peroxidase kit, Vector 
Laboratories). Immunoreactivity was visualized using 3,3’-diaminobenzidine 
tetrahydrochloride dihydrate (DAB) (brown color). Nuclear counterstaining was 
performed with Mayer’s hemalum (blue color). As specificity controls for the 
ligand immunohistochemistry assay, rat GH as well as rat GH plus primary 
antibody were omitted. 
2.3. Blood collection 
Animals were fasted overnight (16 hours) before blood collection from the jugular 
vein. After clotting for 30 minutes at room temperature, serum was separated by 
centrifugation (1200 × g) for 20 minutes at 6°C and stored at -80°C until analysis. 
For repeated blood sampling required to analyze GH secretion profiles, central 
venous catheters (Argon Careflow™; Merit Medical) were surgically inserted 
through the external ear vein. Blood samples were collected every 30 minutes for 9 
hours, starting at 11 a.m., and processed for serum collection as described above. 
During the test, the animals were fed regularly and had free access to water. 
2.4. Clinical chemistry, hormone assays, IGFBP ligand blot analysis 
Clinical-chemical parameters in serum were determined using a Cobas 311 system 
(Hitachi) or an AU480 autoanalyzer (Beckman-Coulter) and adapted reagents from 
Roche Diagnostics or Beckman-Coulter, respectively. Serum GH concentrations 
III. PUBLICATION       30 
were measured by an ELISA for rat/mouse GH (EZRMGH-45K; Merck) that cross-
reacts with porcine GH. To calculate the area under the GH curve, values below the 
quantification limit of the assay (<0.07 ng/mL) were arbitrarily set to 0.07 ng/mL. 
IGF1 levels in serum were determined by RIA after dissociation of IGF1 from 
IGFBPs by acidification and blocking the IGF1 binding sites with an excess of IGF2 
[25]. IGFBP ligand blot analysis of serum samples was performed as described 
previously [26] using serial dilutions of recombinant human IGFBP3 (41/38 kDa), 
IGFBP2 (32 kDa), IGFBP5 (29 kDa) and IGFBP4 (24 kDa) for quantification. 
Plasma insulin was determined using a species-specific RIA (Merck Millipore) as 
previously described [27]. Blood glucose levels were determined immediately 
using a Precision Xceed® glucometer and Precision XtraPlus® test strips (Abbott) 
[28]. Serum leptin levels were measured using a multi-species leptin 
radioimmunoassay (Cat. # XL-85K; EMD Millipore Corporation) that has been 
validated for porcine samples [29]. 
2.5. Growth parameters and body composition 
Body weight and body length (distance between tip of the snout and tail root in 
straightened animals) of GHR-KO and control pigs were determined at weekly 
intervals. Relative body length was calculated by dividing the body length by the 
cube root of the body weight to retain the same dimensions. Since not all animals 
could be weighed/measured at exactly the same ages, raw data were adjusted by 
linear interpolation to defined ages/time points.  
The percentage of total body fat was determined in 6-month-old GHR-KO and 
control pigs using dual-energy X-ray absorptiometry (DXA; Lunar iDXA, GE 
Healthcare) as previously described [30]. In addition, magnetic resonance imaging 
(MRI; Magnetom Open, Siemens) [31] was performed to visualize and determine 
the muscle to fat ratio as the area of longissimus dorsi muscle divided by the area 
of its overlying back fat at the last rib.  
2.6. Necropsy 
GHR-KO and control pigs were euthanized at 6 months of age under anesthesia by 
intravenous injection of T61® (Intervet) and immediately subjected to necropsy. 
Organs were dissected and weighed to the nearest mg. Tissue samples were 
collected as described previously [32] and routinely fixed in neutral buffered 
formalin solution (4 %) for 24 h or frozen immediately on dry ice and stored at -
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80°C for molecular profiling. Formalin-fixed tissue specimens were embedded in 
paraffin. Muscle sections were stained with hematoxylin and eosin (H&E). 
2.7. Immunoblot analysis of signaling cascades 
The concentrations and phosphorylation status of GHR-related signaling molecules 
in the liver were evaluated by Western blot analyses as described previously [33]. 
Briefly, liver tissue samples were homogenized in Laemmli extraction buffer, and 
the protein content was determined by the bicinchoninic acid protein assay. Forty 
micrograms of total protein was separated by SDS-PAGE and transferred to PDVF 
membranes (Millipore) by electro-blotting. Membranes were washed in TBS with 
0.1 % Tween-20 and blocked in 5 % w/v fat-free milk powder (Roth) for 1 hour. 
The membranes were then washed again and incubated in 5 % w/v BSA (Roth) 
solution with the appropriate primary antibodies overnight at 4°C. The antibodies 
and concentrations used are listed in Suppl. Table 1. After washing, the membranes 
were incubated in 5 % w/v fat-free milk powder solution with the secondary 
antibody (donkey anti-rabbit; 1:2000; GE Healthcare) for 1 hour. Bound antibodies 
were detected using the ECL Advance Western Blotting Detection Kit (GE 
Healthcare) and appropriate films from the same supplier. Band intensities were 
quantified using the ImageQuant software package (GE Healthcare).  
2.8. Statistical analyses 
Longitudinal data for body weight and body length or relative body length 
respectively were analyzed using PROC MIXED (SAS 8.2), taking the effects of 
pig line (#2529; #2533), group (GHR-KO; control), sex, age, and interaction 
group*age into account. Least squares means (LSMs) and standards errors (SEs) of 
LSMs were calculated for group*age and compared using Student’s t-tests. Data 
for glucose homeostasis and serum lipid concentrations were analyzed using PROC 
GLM (SAS 8.2), taking the effects of group, sex, age and the interaction group*age 
into account. LSMs and SEs were calculated for group*age and compared using 
Student’s t-tests. Body composition, organ weight and clinical chemical data were 
analyzed using PROC GLM taking the effects of group and sex into account. LSMs 
and SEs were calculated for groups and compared using Student’s t-tests. IGFBP 
ligand blot and Western immunoblot data were evaluated for significant differences 
between GHR-KO and control pigs using the Mann-Whitney U test. 
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3. RESULTS 
3.1. Generation of a growth hormone receptor-deficient pig model 
We employed CRISPR/Cas9 technology to generate GHR knockout (GHR-KO) 
pigs as a large animal model for Laron syndrome (LS). In vitro-transcribed RNA 
encoding Cas9 and sgRNA specific for GHR exon 3 was injected into in vitro 
fertilized porcine oocytes, which were transferred to recipient gilts. In total, 8 
piglets were born, of which 3 showed monoallelic mutations in the GHR gene. Two 
female founder animals carried monoallelic insertions of 1 bp (#2529) or 7 bp 
(#2533) (Fig. 1A). The two founder animals were mated with wild-type boars to 
establish pedigrees for phenotypic analyses of GHR-deficient (GHR-KO) vs. GHR-
expressing F2 animals (Suppl. Fig. 1). The two lines were kept separate except in 
one experiment to test the fertility of GHR-KO pigs. Wild-type, heterozygous and 
GHR-KO littermates were identified by PCR and restriction fragment length 
polymorphisms of the mutated and wild-type GHR alleles (Fig. 1B). Since we did 
not observe significant differences between heterozygous GHR mutant and wild-
type animals (Suppl. Fig. 2), they were pooled and used as the GHR-expressing 
control group. 
3.2. Homozygous frameshift mutations in GHR exon 3 result in 
GHR deficiency 
The insertion of 1 bp (#2529) or 7 bp (#2533) leads to a shift in the reading frame 
in GHR exon 3. The mutant GHR transcripts encode the 18-aa signal peptide and 
51 aa of the extracellular GHR domain, followed by an 18-aa or a 20-aa missense 
sequence and premature termination codon after 87 aa (#2529) or 89 aa (#2533) 
(Fig. 1C). 
The presence of GHR was investigated in liver and kidney sections since these 
tissues naturally express high levels of GHR [34]. To evaluate GH binding, the 
sections were incubated with recombinant GH, and bound GH was detected using 
specific antibodies. This ligand immunohistochemistry approach showed strong 
GH binding in control tissues, while GH binding was absent in tissue sections from 
GHR-KO animals (Fig. 1D). 
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Figure 1. Generation of a GHR-deficient pig model using CRISPR/Cas technology. 
(A) Partial DNA sequence of GHR exon 3. The sgRNA binding site is indicated in 
blue and the protospacer adjacent motif (PAM) in green. Insertions (red) of 1 bp 
(founder #2529) or 7 bp (founder #2533) lead a shift of the reading frame. WT = 
wild type. (B) Restriction fragment length polymorphism analysis to detect the WT 
GHR sequence as well as monoallelic (Het) and biallelic (KO) mutations. (C) 
Partial amino acid sequences encoded by the WT and mutant GHR alleles. The 
signal peptide is shown in gray, WT GHR aa sequence in black (aa encoded by 
adjacent non-symmetrical exons in blue), missense aa sequence in red, and the 
premature termination codon as an asterisk. (D) Ligand immunohistochemistry 
demonstrating the absence of functional GHR (brown staining in control) in GHR-
KO pigs. Chromogen: DAB; counterstain: Mayer’s hemalum; bar = 10 µm. 
3.3. Decreased serum IGF1 and IGFBP3, and increased IGFBP2 in 
GHR-KO pigs 
GHR-KO pigs of all ages showed a marked reduction in serum insulin-like growth 
factor 1 (Fig. 2A,B). IGF binding proteins (IGFBPs) were evaluated by ligand blot 
analysis in 6-month-old animals using a dilution series of recombinant human 
IGFBPs for quantification (Fig. 2C). IGFBP3 was significantly decreased in 
GHR-KO pigs (426 ± 41 µg/L vs. 1775 ± 205 µg/L in control animals; p < 0.0001), 
while IGFBP2 was significantly increased (799 ± 53 µg/L vs. 607 ± 66 µg/L in 
control animals; p = 0.0272) (Fig. 2D).  
3.4. GHR-KO pigs have high levels of circulating GH 
To evaluate effects of GHR deficiency on the pulsatile secretion of GH, we 
collected serial blood samples at 30-min intervals over a period of 9 hours (starting 
at 11 a.m.) from five female and one male 9-month-old GHR-KO pig and from six 
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age-matched female controls. Serum GH levels of GHR-KO pigs were high with 
partially preserved pulsatility (area under the GH curve was increased 6.8-fold in 
GHR-KO compared with control pigs), indicating a disturbance in the negative 
feedback control of GH secretion (Fig. 2E,F; Suppl. Fig. 3). 
 Figure 2. Serum IGF1, IGFBP and GH concentrations of GHR-KO compared with 
control pigs. (A) Scatter plot of serum IGF1 levels of GHR-KO and control pigs 
over time. (B) Means and standard deviations of all serum IGF1 values displayed 
in panel A (GHR-KO: n = 42; control: n = 69). (C) Representative IGFBP ligand 
blot. Right lane displays recombinant human IGFBP3 (41/38 kDa), IGFBP2 (32 
kDa), IGFBP5 (29 kDa) and IGFBP4 (24 kDa). (D) Quantification of IGFBP3 and 
IGFBP2 in serum from GHR-KO (n = 10) and control pigs (n = 12). The figure 
shows medians, 25th and 75th percentiles (box), and extremes (whiskers). (E) 
Representative GH secretion profiles of two female GHR-KO and two female 
control pigs. (F) Area under the GH curve (AUC; means and standard deviations 
for 6 female GHR-KO and 5 female/1 male control pigs). AU = arbitrary units. *p 
< 0.05; ***p < 0.001.  
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3.5. GHR-KO pigs show severe growth retardation 
The birth weight of GHR-KO piglets did not differ from control littermates. First 
significant growth retardation became obvious at five weeks of age (p = 0.045), 
leading to a 62 % reduction in body weight of 6-month-old GHR-KO pigs 
(33.0 ± 1.5 kg) compared with age-matched control animals (86.2 ± 1.1 kg; p < 
0.0001) (Fig. 3A,B). Body length at birth did not differ between GHR-KO and 
control piglets (33.9 ± 1.4 cm vs. 37.3 ± 1 cm; p = 0.4068). Significant differences 
in body length appeared at four weeks of age (52.2 ± 1.4 cm in GHR-KO vs. 
60.3 ± 1 cm in control animals; p < 0.0001). At six months of age, the body length 
of GHR-KO pigs was reduced by 27 % compared with control pigs (100.6 ± 1.6 cm 
vs. 138.1 ± 1.4 cm; p < 0.0001) (Fig. 3C). Up to an age of four months, weight gain 
was more affected than linear growth by GHR deficiency, as indicated by an 
increased relative body length (body length divided by the cube root of body 
weight) of GHR-KO pigs (Fig. 3D). No growth parameters exhibited significant 
sex-related differences.  
 Figure 3. Body 
weight gain and 
growth of GHR-KO 
compared with 
control pigs. (A) 
GHR-KO pig (front) 
and control 
littermate aged 6 
months. (B) Body 
weight gain. (C) 
Body length. (D) 
Relative body 
length (body length 
divided by the cube 
root of body weight. 
These parameters 
were determined in 
12 GHR-KO and 25 control pigs. Panels A-D show least squares means (LSM) and 
standard errors of LSM estimated for group*age (see 2.8 for the statistical model). 
*p < 0.05; **p < 0.01; ***p < 0.001; ns = not significant. 
3.6. GHR-KO pigs show an increased proportion of body fat and a 
reduced ratio of muscle to fat tissue 
DXA analysis revealed a markedly increased percentage of total body fat in 6-
month-old GHR-KO pigs (21.5 ± 0.7 % vs. 11.4 ± 0.5 % in age-matched control 
animals; p < 0.0001) (Fig. 4A). While female pigs in the control group displayed 
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significantly higher body fat content than male pigs (13.2 ± 0.7 % vs. 9.6 ± 0.7 %; 
p = 0.0009), no sex-related differences were observed in GHR-KO pigs (22.9 ± 1 % 
in males vs. 22 ± 1 % in females; p = 0.4530). To determine the ratio of muscle to 
fat tissue, MRI scans were performed at the location of the last rib, and the volume 
ratio of the longissimus dorsi muscle and its overlying back fat was calculated (Fig. 
4B,C). GHR-KO pigs showed a significantly reduced muscle to fat tissue ratio 
compared with control pigs (3.0 ± 0.6 vs. 8.2 ± 0.4; p < 0.0001) (Fig. 4B). No sex-
related differences were observed in this parameter (Suppl. Table 2).  
 Figure 4. Body 
composition of 6-
month-old GHR-KO 
compared with control 
pigs. (A) DXA analysis 
revealed a significantly 
higher amount of total 
body fat in GHR-KO 
pigs. (B) The calculated 
ratio of muscle to fat 
tissue from MRI images 
at the last rib revealed a 
significant shift towards 
fat tissue in GHR-KO 
pigs (GHR-KO: n = 12; 
control: n = 25; ***p < 
0.001). Panels A and B 
show least squares 
means (LSM) and 
standard errors of LSM 
estimated for the 2 
groups (see 2.8 for the 
statistical model). (C) 
Representative magnetic 
resonance images used 
to evaluate the volume 
of the longissimus dorsi 
muscle (mu) and its 
overlying back fat (ft) at the last rib in GHR-KO and control pigs. Note the larger 
subcutaneous and visceral fat depots in GHR-KO pigs. (D) Representative 
macroscopic cross-sections of the first lumbar vertebra, the two longissimus dorsi 
muscles and the overlaying back fat and skin. (E) Higher magnification of D 
showing an increased ratio of subcutaneous fat (ft) to skin (sk) thickness in a GHR-
KO compared with a control pig. Histological section (H&E stain) showing an 
increased amount of intramuscular fat in GHR-KO pigs (bar = 100 µm). 
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The MRI findings were confirmed upon necropsy, showing a marked increase in 
the thickness of the subcutaneous fat tissue and a reduction in the size of the 
longissimus dorsi muscle in GHR-KO pigs (Fig. 4D,E). Histological sections of 
skeletal muscle samples from GHR-KO pigs revealed markedly increased numbers 
of adipocyte section profiles between muscle fibers (Fig. 4E). 
3.7. Disproportionate organ growth of GHR-KO pigs 
In 6-month-old GHR-KO pigs, absolute weights of all organs were significantly 
smaller than in age-matched control animals (Fig. 5, Suppl. Table 3). Most organ 
weights of GHR-KO pigs were reduced proportionally to body weight. However, 
the relative weights of liver (73 % of control animal relative liver weight; 
Figure 5. Disproportionate organ growth in GHR-KO compared with control 
pigs. GHR-deficiency led to a proportionate and disproportionate reduction in 
organ sizes. (A) Representative organs from control (left) and GHR-KO pigs 
(right). (B) Relative differences between GHR-KO and control pigs in absolute 
organ weights and in organ weight-to-body weight ratios (relative organ weights). 
These parameters were determined in 9 GHR-KO and 25 control pigs, and least 
squares means (LSM) and standard errors of LSM were estimated for the 2 groups 
(see 2.8 for the statistical model). *p < 0.05; **p < 0.01; ***p < 0.001. 
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p = 0.0005), kidneys (73 % of control animal relative kidney weight; p = 0.0002) 
and heart (87 % of control animal relative heart weight; p = 0.0119) were 
significantly reduced, while relative brain weight was doubled (200 % of control 
animal relative brain weight; p < 0.0001) (Fig. 5, Suppl. Table 3). 
3.8. Male and female GHR-KO pigs are fertile 
The ovaries of 6-month-old GHR-KO gilts did not show obvious morphological 
differences from control ovaries. Mating of an 8-month-old GHR-KO boar (line 
#2529) with a GHR-KO sow (line #2533) of the same age resulted in a litter of 6 
healthy GHR-KO piglets (Suppl. Fig. 4A). Their birth weight tended to be reduced 
in comparison to GHR-KO piglets derived from heterozygote × heterozygote 
matings (on average 0.75 kg compared with 1.3 kg). However, the animals showed 
catch-up growth and achieved a higher body weight at 6 months of age than 
GHR-KO offspring from heterozygous GHR-KO parents (43.8 ± 1.3 kg vs 
33.0 ± 2.2 kg; p < 0.0001; Suppl. Fig. 4B).  
3.9. GHR-KO pigs show transient hypoglycemia, while insulin levels 
remain unaffected 
Young GHR-KO pigs (12 to 15 weeks old) showed significantly reduced fasting 
blood glucose levels (41.5 ± 3.8 mg/dL vs. 63.1 ± 3.1 mg/dL in age-matched 
control animals; p = 0.0001), while this difference disappeared in older animals (23 
to 27 weeks) (Fig. 6A). Fasting serum insulin levels of GHR-KO pigs did not differ 
from control pigs at any age (Fig. 6B). In addition, the homeostatic model 
assessment (HOMA) for evaluating insulin resistance was calculated from fasting 
glucose and insulin concentrations. In agreement with their low fasting blood 
glucose concentrations, HOMA-IR values of young GHR-KO pigs tended to be 
reduced (0.25 ± 0.20 vs. 0.76 ± 0.19 in age-matched control pigs; p = 0.0635), but 
increased to 0.76 ± 0.18 in the older age group (p = 0.0839), when controls had a 
HOMA-IR of 0.43 ± 0.20 (p = 0.2584; Fig. 6C). Analysis of variance revealed a 
significant (p < 0.05) interaction of group*age. 
3.10. Serum lipid levels are reduced in young GHR-KO pigs 
Young GHR-KO pigs (aged 12 to 15 weeks) revealed significantly decreased serum 
concentrations of triglycerides (23.2 ± 6.8 mg/dL vs. 42.3 ± 4.9 mg/dL in controls; 
p = 0.021; Fig. 6D), cholesterol (70 ± 3.5 mg/dL vs. 81.8 ± 2.8 mg/dL in controls; 
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p = 0.0129; Fig. 6E), low-density lipoprotein (LDL)-cholesterol (42.8 ± 2.7 mg/dL 
vs. 50.1 ± 2.1 mg/dL in controls; p = 0.0392; Fig. 6F) and high-density lipoprotein 
(HDL)-cholesterol (29.0 ± 1.6 mg/dL vs. 33.8 ± 1.3 mg/dL in controls; p = 0.0224; 
Fig. 6G). In older GHR-KO pigs (23 to 27 weeks), serum triglyceride, cholesterol 
and LDL-cholesterol concentrations were similar to those of control pigs, while 
serum HDL-cholesterol levels were increased (32.5 ± 1.3 mg/dL vs. 28.6 ± 1.0 
mg/dL in controls; p = 0.0272) (Fig. 6D-G). Excluding triglycerides, all 
investigated lipid parameters were significantly (p < 0.0002) affected by sex, with 
higher levels in female than in male animals (Suppl. Table 4). 
Figure 6. Age-dependent 
changes in glucose and 
lipid homeostasis 
parameters in GHR-KO 
and control pigs. (A) 
Transient juvenile 
hypoglycemia in GHR-
KO pigs. B) Unchanged 
serum insulin 
concentrations. C) 
Initially lower, then 
higher HOMA-IR score 
(interaction group*age: p 
< 0.05). Serum 
concentrations of (D) 
triglycerides, (E) 
cholesterol, (F) low-
density lipoprotein 
(LDL) and (G) high-
density lipoprotein levels 
were significantly lower 
in young GHR-KO pigs 
than in age-matched 
controls, but normalized 
with age. HDL levels of 
23- to 27-week-old GHR-
KO pigs were even 
higher than in their 
control littermates. At 
least 6 animals per group 
and age-class were 
investigated. Panels A-G 
show least squares means 
(LSM) and standard errors of LSM estimated for group*age (see 2.8 for the 
statistical model). *p < 0.05; **p < 0.01. 
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3.11. Additional alterations of clinical-chemical parameters in GHR-
KO pigs 
To screen for changes in organ functions and metabolic pathways, a broad spectrum 
of clinical-chemical parameters in serum of 6-month-old GHR-KO and control pigs 
were analyzed. While all parameters remained within physiological ranges, 
GHR-KO pigs displayed lower levels of creatinine (91.2 ± 6.5 µmol/L vs. 
126.4 ± 5.0 µmol/L in controls; p = 0.0004) but higher levels of urea (7.4 ± 0.5 
mmol/L vs. 4.3 ± 0.3 mmol/L in controls; p < 0.0001) (Suppl. Table 5). 
3.12. GHR-KO pigs display significant changes in the activation of 
hepatic signaling cascades 
Since the liver is a major target tissue of insulin and GH, we evaluated changes in 
associated signaling cascades by Western blot analyses of liver samples from fasted 
6-month-old GHR-KO and control animals.  
The total amount of insulin receptor (INSR) and of phosphorylated INSR were 
unchanged in GHR-KO liver samples. In contrast, the concentrations of total and 
phosphorylated insulin receptor substrate 1 (IRS1) were significantly (p = 0.0159) 
increased in liver samples from GHR-KO vs. control pigs. The investigation of 
signal transducers downstream of the INSR revealed significantly increased 
phosphorylation of phosphoinositide 3 kinase (PI3K) and a trend (p = 0.0635) 
toward an increase in serine/threonine protein kinase AKT phosphorylation in 
GHR-KO liver samples. Furthermore, a trend (p = 0.0635) toward increased levels 
of total peroxisome proliferator-activated receptor gamma (PPARG) was observed 
(Fig. 7A). 
GHR-KO liver samples showed significantly increased phosphorylation levels of 
Janus kinase 2 (JAK2). The phosphorylation levels of signal transducer and 
activator of transcription 5 (STAT5) were significantly reduced, while STAT3 
phosphorylation showed a tendency to increase (p = 0.1111). Phosphorylation of 
STAT1 was not significantly different between GHR-KO and control pigs, whereas 
significantly increased phosphorylation levels of mitogen-activated protein kinase 
(MAPK) were detected (Suppl. Fig. 5).  
In addition, liver extracts from GHR-KO pigs showed a significant increase in 
phosphorylated mechanistic target of rapamycin (mTOR), which was not detected 
in control liver samples. To distinguish between the activation of mTOR complex 
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1 (mTORC1) and 2 (mTORC2), we analyzed several specific up– and downstream 
signal transducers for each complex [35, 36] (Fig. 7B; Suppl. Fig. 5).  
Figure 7. Western blot analysis of signaling cascades in liver samples of 6-month-
old fasted GHR-KO (n = 5) and control pigs (n = 4). (A) Insulin receptor-related 
signaling pathway and PPARG. (B) GHR- and mTOR-related signaling pathways. 
The box plots show medians, 25th and 75th percentiles (box), and extremes 
(whiskers). *p < 0.05; °p = 0.0635; evaluated using the Mann-Whitney U test. 
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A key element of mTORC1 action is protein S6 kinase 1 (S6K), which 
phosphorylates S6. GHR-KO liver samples did not show increased phosphorylation 
of S6K (Fig. 7B). Phosphorylation of other effectors downstream of mTORC1 - 
eukaryotic initiation factor 4E binding protein 1 (4EBP1) and eukaryotic 
translation initiation factor 4E (eIF4E) - was unchanged in GHR-KO liver 
samples (Suppl. Fig. 5). Phosphorylation of AMP-activated protein kinase 
(AMPK), an inhibitor of mTORC1, was significantly increased in GHR-KO liver 
tissue (Suppl. Fig. 5). Collectively these data suggest that mTORC1 is not activated 
in liver of GHR-KO pigs.  
In contrast, one of the most important downstream substrates of mTORC2 - 
glycogen synthase 3 beta (GSK3B) – showed significantly increased 
phosphorylation in GHR-KO liver tissue (Fig. 7B). Furthermore, the 
phosphorylation levels of potent regulators of mTORC2 action, PI3K and AKT, 
were also increased (Fig. 7A). These findings suggest that mTORC2 is activated in 
the liver of GHR-deficient pigs. A summary of these findings is provided in Fig. 
8A. 
3.13. Serum leptin levels and hepatic leptin receptor activation are 
increased in GHR-KO pigs 
Considering the expected reduced STAT5 phosphorylation but unexpected 
increased JAK2 phosphorylation in the liver of GHR-KO pigs, we measured serum 
leptin levels and hepatic leptin receptor (LEPR) activation. LEPR signaling 
involves activation of JAK2 and STAT3, but not STAT5 (reviewed in 37). Overall, 
serum leptin concentrations of 6-month-old fasted GHR-KO pigs were significantly 
elevated compared with the controls (Fig. 8B), with higher levels in females than 
in males (Suppl. Table 2). In addition, LEPR phosphorylation was significantly 
increased in GHR-KO vs. control liver samples (Fig. 8C). 
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Figure 8. (A) Schematic summary of the changes in phosphorylation in INSR- and 
GHR-related signaling molecules in liver samples of GHR-KO compared with 
control pigs. *p < 0.05; °p = 0.0635; evaluated using the Mann-Whitney U test. (B) 
Significantly increased fasting serum leptin concentrations in 6-month-old GHR-
KO vs. control pigs. The figure shows the estimated least squares means (LSM) and 
standard errors of the LSM for the two groups, taking into account the effect of sex 
(9 male/13 female control pigs; 6 male/6 female GHR-KO pigs). **p < 0.01 for the 
effect of group (PROC GLM). (C) Significantly increased expression and 
phosphorylation of LEPR in liver samples from GHR-KO compared with control 
pigs. PC = protein lysate from choroid plexus of a wild-type pig used as positive 
control. *p < 0.05; evaluated using the Mann-Whitney U test. 
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4. DISCUSSION 
This study reports a new large animal model for GHR deficiency (Laron syndrome, 
LS). Previously described pig models with impaired GH function, which are either 
GHR-deficient [38] or express a dominant negative GHR [39], were established on 
a minipig background that is already growth impaired and may thus not resemble 
all pathophysiological consequences of human LS. Therefore, we established our 
GHR-deficient model on a German landrace background with the physiological 
growth potential of domestic pigs and performed a comprehensive characterization 
of body and organ growth, body composition, endocrine and metabolic changes, 
and signaling cascades in liver. 
Our GHR-deficient pig model exhibits important hallmarks of human LS, such as 
insensitivity to GH, low circulating IGF1 concentrations, and reduced postnatal 
body and organ growth. Similar findings have been reported for minipig models 
with impaired GH function [38, 39]. Our study provides a more comprehensive 
phenotypic analysis, including serial GH measurements, effects on serum IGFBPs, 
age-dependent changes in glucose homeostasis and lipid profiles, and analyses of 
hepatic signaling cascades. 
Circulating IGF1 originates in large part from the liver, as shown by liver specific 
Igf1 KO mice [40], and is complexed by high-affinity IGFBPs, with IGFBP3 and 
an acid labile subunit (ALS) forming a 150-kDa complex, which is the main 
reservoir of IGF1 in the bloodstream (reviewed in 41, 42). ALS is directly regulated 
by GH, and reduced ALS levels are observed in GHR-deficient patients [43]. The 
production of IGFBP3 is also stimulated by GH [44], and GHR deficiency in mice 
and humans leads to reduced levels of IGFBP3 in the circulation [15, 45]. In 
agreement with these reports, serum IGFBP3 concentrations of GHR-KO pigs were 
significantly reduced, presumably leading to a decrease in the IGF1 reservoir in the 
circulation and thus to a shortened half-life. In addition, the concentration of 
IGFBP2 was increased in serum of GHR-KO pigs. Studies in transgenic IGFBP2-
overexpressing mice have shown that IGFBP2 inhibits the growth of normal [46] 
and even of GH-overexpressing mice [47]. Therefore, the reduced growth of GHR-
KO pigs most likely results from a combination of a decline in the production and 
half-life of circulating IGF1 and, possibly, IGF1 sequestration by inhibitory 
IGFBP2. 
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Circulating IGF1 is also responsible for the feedback inhibition of pituitary GH 
secretion (reviewed in 48). In accordance with this concept, GHR-KO pigs with low 
serum IGF1 levels showed high serum GH concentrations with partially preserved 
pulsatility. Serial blood samples for the analysis of hormone profiles can be 
obtained easily from pigs equipped with permanent central venous catheters [49], 
whereas serial blood sampling in mice is more difficult. 
Interestingly, a growth deficiency phenotype of GHR-KO pigs was observed no 
earlier than postnatal week 5, which indicated that GH was not required as promoter 
of intrauterine and early postnatal growth. This finding is consistent with 
observations in infants with LS [50] and in neonatal Ghr KO mice [15]. Instead, 
intrauterine growth depends on IGF2 and IGF1, the latter of which acts 
independently of GH during this period of development [51]. An essential role of 
GH as a postnatal growth promoter has been established during the maturation of 
the endocrine growth axis, which is associated with an increase in expression of 
hepatic GHR [52]. In general, intrauterine maturation of endocrine functions in pigs 
is similar to humans, whereas rodents are born in a more immature state (reviewed 
in 53).  
In agreement with observations in human LS patients [54] and Ghr KO mice [55], 
GHR-KO pigs displayed an increase in total body fat and a decrease in the muscle 
to fat ratio. Adipose tissue mass is determined by the storage and removal of 
triglycerides in adipocytes. A recent study in which human adipocyte lipid age was 
determined by measuring 14C from nuclear bomb tests revealed that triglycerides 
are renewed up to 6 times during the average adipocyte life-span of 10 years [56]. 
In GHR-KO pigs, physiological adipocyte lipid turnover is apparently disturbed at 
different levels. First, the lipolytic action of GH via an increase in adipose tissue 
hormone-sensitive lipase (HSL) activity (reviewed in 16, 57) is lost in the absence 
of GHR. Second, the synthesis of storage lipids in adipocytes is likely to increase 
in GHR-KO pigs. This phenomenon requires hydrolysis by lipoprotein lipase (LPL) 
of the triglyceride component of circulating chylomicrons and very low-density 
lipoproteins (VLDL) into free fatty acids and 2-monoacylglycerol, which can be 
taken up by adipocytes. Adipose tissue LPL activity is increased by insulin but 
inhibited by GH and sex steroids (reviewed in 58). Reduced serum triglyceride 
levels in young GHR-KO pigs (12-15 weeks) with normal insulin levels, but lacking 
the counteracting effects of GH and sex steroids, may reflect an increased use of 
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triglycerides for lipid synthesis in adipocytes, leading to an increase in total body 
fat. In older GHR-KO pigs (23-27 weeks), the increased total body fat content may 
lead to decreased triglyceride turnover of adipocytes [56], limiting the use of 
circulating triglycerides for storage lipid synthesis in adipocytes. Furthermore, the 
animals became sexually mature, with sex steroids potentially inhibiting adipose 
tissue LPL and the hydrolysis of serum triglycerides, thus resulting in normal serum 
triglyceride levels. Decreased serum cholesterol levels, as observed in young GHR-
KO pigs, have also been reported in human LS patients [3] and Ghr KO mice 
(reviewed in 16). 
Measurements of organ weights in GHR-KO pigs revealed that growth of liver, 
kidneys and heart is particularly dependent on GHR/GH action, as their relative 
weights were significantly decreased in comparison to control pigs. Reduced 
relative liver and kidney weights have also been observed in Ghr KO mice [55], 
and interestingly LS patients have disproportionately reduced cardiac dimensions 
[59]. The important role of the GH/IGF1 system in the growth of these organs is 
supported by their disproportionate overgrowth in conditions of GH/IGF1 excess, 
as in GH-overexpressing transgenic mice [60, 61] and in patients with acromegaly 
[62]. In contrast, brain growth is less dependent on intact GHR signaling, as shown 
by a relatively moderate reduction in absolute brain weight and a marked increase 
in the relative brain weight of GHR-KO pigs. Based on similar observations in Ghr 
KO mice, Sjogren et al. [63] speculated that a large proportion of brain growth 
occurs relatively early in development in a GH-independent stage.  
Patients with Laron syndrome exhibit delayed puberty, but they are able to achieve 
full sexual development and reproduce [2]. In Ghr KO mice, delayed puberty and 
reduced litter sizes have been observed. The latter has been attributed to reduced 
ovarian function due to the lack of IGF1 (reviewed in 16). To assess the fertility of 
GHR-KO pigs, a GHR-KO boar and a GHR-KO sow were mated, resulting in a 
litter of 6 healthy piglets. Although not significant, the mean birth weight of these 
piglets was 40 % lower than that of GHR-KO piglets from a heterozygote x 
heterozygote mating, most likely because of the limited fetal growth capacity of a 
smaller mother. Interestingly, GHR-KO piglets from homozygous parents showed 
catch-up growth and had a 33 % higher body weight at six months than GHR-KO 
piglets from heterozygous parents. An explanation for this increased growth 
performance may be hybrid vigor, potentially resulting from the mating of GHR-
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KO pigs from two different lines (Suppl. Fig. 1). 
GHR-KO pigs showed juvenile hypoglycemia that normalized when the animals 
reached sexual maturity. Hypoglycemia is a hallmark of juvenile age LS [3, 64] and 
has been mainly explained by the lack of stimulatory GH effects on hepatic 
gluconeogenesis (reviewed in 57). Contrasting observations have been obtained 
concerning the role of altered insulin sensitivity in the development of juvenile 
hypoglycemia (reviewed in 65). While no evidence for increased insulin sensitivity, 
and even some cases of insulin-resistant diabetes mellitus, have been reported in 
the Israeli cohort of LS patients [64, 66], individuals from the Ecuadorian LS cohort 
are more insulin-sensitive than their GHR intact relatives [67], and no cases of 
diabetes mellitus were reported [7]. The reasons for this discrepancy remain elusive 
[65]. Although HOMA-IR is not a routinely established parameter to assess insulin 
(in)sensitivity in pigs (reviewed in 68), the trend (p=0.0635) toward lower HOMA-
IR scores in young GHR-KO vs. control pigs suggests that increased insulin 
sensitivity is a contributing factor to juvenile hypoglycemia, as also observed in 
some Ghr KO mouse models (69; reviewed in 16). While the HOMA-IR scores of 
GHR-KO pigs increased with age, and tended to be higher in sexually mature GHR-
KO than in age-matched control pigs (interaction group*age: p < 0.05), there was 
no evidence for insulin resistance. Interestingly, we observed increased levels of 
total and phosphorylated IRS1 in liver samples from fasted adult GHR-KO pigs, 
which could represent a mechanism for increased insulin sensitivity. Similar 
observations and conclusions were obtained in GH-deficient Ames dwarf mice with 
increased insulin sensitivity [70]. Future studies involving state-of-the-art in vivo 
measurements of gluconeogenesis [71] and investigation of insulin sensitivity using 
hyperinsulinemic, euglycemic clamp studies in juvenile and sexually mature GHR-
KO and control pigs will help to clarify the relative contributions of these 
mechanisms to juvenile hypoglycemia in LS and its normalization in adult LS 
patients. Such studies can be performed more accurately in pigs than in rodent 
models due to their larger size [49]. 
While all clinical-chemical parameters measured in the serum of GHR-KO pigs 
remained within the normal reference ranges for pigs, creatinine levels were 
reduced and serum urea concentrations were increased compared with the control 
pigs. The serum creatinine concentration correlates with muscle mass [72], which 
explains the reduced levels in GHR-KO pigs and in LS patients [3]. Increased serum 
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concentrations of urea, the end product of amino acid catabolism in mammals, have 
also been detected in Ghr KO mice [69] and are most likely due to IGF1 deficiency 
and the lack of its protein anabolic action (reviewed in 73).  
Since the liver is a major target organ for GH, we investigated alterations in the 
activity of selected hepatic signaling pathways in adult fasted GHR-KO and control 
pigs. Upon binding of GH, the GHR homodimer undergoes a conformational 
change that brings the originally parallel receptor transmembrane domains into a 
rotated crossover orientation, thus separating the lower parts of the transmembrane 
helices. Thereby, the two JAK2 molecules that are associated with the membrane 
proximal Box1 motif of the GHR chains are separated, and the inhibitory 
pseudokinase domain of one JAK2 is removed from the kinase domain of the other 
JAK2 and vice versa [74]. The kinase domains of the 2 JAK2 molecules can then 
be transactivated and initiate tyrosine phosphorylation of the GHR cytoplasmic 
domains and STAT5, the key transcription factor mediating most genomic actions 
of GH (reviewed in 75), including stimulation of IGF1 gene expression [76]. In 
agreement with this concept, the phosphorylation of STAT5 in liver of GHR-KO 
pigs was significantly reduced and the circulating IGF1 levels were markedly 
decreased compared with control pigs. However, unexpectedly, phosphorylation of 
JAK2 was significantly increased in liver of GHR-KO pigs, together with a 
significant increase in the phosphorylation of MAPK, PI3K, and mTOR, which are 
known to be – directly or indirectly – activated by JAK2 [77].  
In addition to GHR, many other class I cytokine receptors also use the non-receptor 
tyrosine kinase JAK2 for signaling, including the receptors for erythropoietin, 
prolactin, interleukins 3, 5 and 6, granulocyte-macrophage colony-stimulating 
factor, interferon-gamma, thrombopoietin, and leptin (reviewed in 78). GHR is 
abundantly expressed in liver and can dimerize and associate with JAK2 in the 
absence of GH (reviewed in 75). Since GHR-bound JAK2 can only be activated in 
the presence of GH, elimination of GHR may increase the pool of JAK2 that can 
be phosphorylated by other class I cytokine receptors. In addition, the loss of GHR 
may alter the abundance of these receptors or their ligands and thus lead to increased 
JAK2 phosphorylation. 
A candidate is leptin, since increased serum leptin levels have been detected in LS 
patients [79] and in the Ghr KO mouse model (reviewed in 16). Leptin is known to 
induce the expression of its receptor in liver [80], and leptin receptor activation 
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involves the phosphorylation of JAK2 and STAT3, but not STAT5 (reviewed in 
37). Consistent with this hypothesis, we observed significantly increased serum 
leptin levels and increased expression and phosphorylation of leptin receptors in 
liver of GHR-KO pigs, providing a potential explanation for the significantly 
increased phosphorylation of JAK2, while phosphorylation of STAT5 was 
significantly reduced.  
Phosphorylation of the serine/threonine kinase mTOR that forms the catalytic core 
of mTOR complex-1 (mTORC1) and mTORC2 was significantly increased in 
GHR-KO pigs. While mTOR phosphorylation was not directly investigated in Ghr 
KO mice, Dominick et al. [35] have evaluated the activities of mTORC1 and 
mTORC2 in fed and fasted animals based on the phosphorylation status of 
downstream substrates of these complexes. In fasted Ghr KO mice, the authors 
observed reduced phosphorylation of the ribosomal protein S6, while the 
phosphorylation status of S6K and 4EBP1 was unaltered compared with control 
mice. In fed Ghr KO mice, the phosphorylation status of all three indicators of 
mTORC1 activity was significantly reduced. In contrast, the phosphorylation level 
of several target substrates of mTORC2, including AKT, was significantly 
increased in fasted Ghr KO vs. control mice, while this difference disappeared after 
feeding [35]. The authors concluded that mTORC2 activity was increased in Ghr 
KO mice – at least in fasted animals - whereas mTORC1 activity was unaltered or 
reduced in fasted and fed Ghr KO mice, respectively. Our study of liver samples 
from fasted GHR-KO pigs did not reveal an increase in the phosphorylation of S6K 
or of 4EBP1 that would trigger its dissociation from eIF4E and allow cap-dependent 
mRNA translation (reviewed in 36). Moreover, we observed a significant increase 
in phosphorylation (= activation) of the mTORC1 inhibitor AMPK [81]. 
Collectively, these findings argue against a major activation of mTORC1 in liver 
of GHR-KO pigs. In contrast, a significant increase in GSK3B phosphorylation and 
a trend (p = 0.0635) toward an increase in AKT phosphorylation suggested a rise in 
the activity of mTORC2. While mTORC1 has profound effects on mRNA 
translation, metabolism and protein turnover, mTORC2 signaling is implicated in 
the regulation of ion transport, apoptosis, glucose metabolism, cell migration and 
cytoskeleton rearrangement (reviewed in 36). Future molecular profiling studies of 
liver and other tissues from GHR-KO and control pigs will clarify whether these 
biological processes are altered in the absence of GHR signaling. 
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Another interesting observation in liver samples from GHR-KO pigs was the trend 
(p = 0.0635) toward an increased abundance of PPARG. Discrepant findings have 
been reported regarding the consequences of increased PPARG activity in liver, 
ranging from the promotion of hepatic steatosis through the upregulation of genes 
involved in lipid uptake and storage, to the prevention of hepatic steatosis and 
fibrosis, possibly by sequestering fatty acids in adipose tissue and preventing 
hepatic stellate cell activation (reviewed in 82). Studies of GHR-KO and control 
pigs, e.g., after being fed a high-fat diet, may provide additional insight into these 
mechanisms. 
One of the most striking effects of GHR deficiency is the increased life-span that 
has been observed in Ghr KO mice [83, 84]. Moreover, patients with LS show 
reduced incidences of cancer and diabetes, associated with reduced pro-aging 
signaling in cells incubated with serum derived from these patients [7]. While life 
expectancy studies in humans are difficult due to their long duration and to multiple 
confounding factors, they are possible in pigs, which can be maintained under 
standardized conditions and have a normal life expectancy of 15 to 17 years 
(reviewed in 85). Moreover, protective effects of GHR deficiency against tumors 
and diabetes can be evaluated by crossing the GHR KO mutation in existing pig 
models that are genetically predisposed to tumor development (e.g., [86]) or (pre-
)diabetes [27, 87], thus bridging the gap between rodents and humans in longevity 
research with tailored large animal models. In addition to these long-lasting in vivo 
experiments, the effects of GHR deficiency on resistance to stress – such as UV 
light and heat – may be evaluated in primary cell cultures from GHR-KO pigs, 
similarly to studies that have been performed using cultured cells from dwarf mice 
[88].  
Investigation of the neurological consequences of GHR deficiency is another 
interesting field, since mental retardation has been reported in a proportion of LS 
patients [2], while subjects from the Ecuadorian cohort display normal intelligence 
[89] or even enhanced cognitive performance [90]. As sophisticated methods for 
testing cognitive functions of pigs are available [91], the GHR-KO pig may also 
serve as a model to address these questions.  
Finally, GHR-KO pigs are interesting animal models for developing and evaluating 
the efficacy and safety of new treatment options for LS, such as PASylated IGF1 
with a prolonged plasma half-life [92]. In addition, it would be interesting to 
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determine whether the phenotype of GHR-KO pigs can be rescued by correction of 
the GHR mutation in a proportion of liver cells via gene editing. In a mouse model, 
hydrodynamic injection into the tail vein has been used to deliver components of a 
CRISPR/Cas9 system to correct a mutated fumarylacetoacetate hydrolase (Fah) 
gene in hepatocytes in vivo [93]. In pigs, refined techniques are available for direct 
application into the liver [94, 95].  
In summary, GHR-KO pigs resemble important aspects of the pathophysiology of 
Laron syndrome and are thus an interesting model for mechanistic studies and 
treatment trials.  
 
Acknowledgments. The authors thank Christina Blechinger, Luong Chau, Tamara 
Holy, Eva-Maria Jemiller, Sebastian Kaidel, Franziska Kress, and Tatjana Schröter 
for excellent technical assistance, and Christian Erdle, Sylvia Hering, and Harald 
Paul for expert animal management. 
 
Funding. This study was supported in part by the German Center for Diabetes 
Research (DZD) and by the German Research Council (TRR127).  
 
Duality of Interest. No potential conflicts of interest relevant to this article are 
reported. 
 
Author Contributions. A. Hi., B. K., M. D. and E. W. conceived the experiments. 
A. Hi. and E. W. wrote the manuscript. All authors contributed to the manuscript 
and read and approved the final version. M. D., S. B., and H. L. developed the 
CRISPR/Cas system for GHR KO. B. K., M. K. and H. N. performed the in vitro 
fertilization, microinjection and embryo transfer experiments; A. Hi. and B. K. 
managed the breeding and performed the phenotypic characterization of GHR-KO 
and control pigs. A. Hi., A. B., and R. W. performed the necropsies. E. K. conducted 
the GHR ligand immunohistochemistry. M. B. and A. M. S. performed the DXA 
and MRI studies. A. Ho. carried out the IGFBP ligand blots analyses. W. F. B. and 
M. B. performed the IGF1 and GH assays. S. R. performed the insulin and glucose 
III. PUBLICATION       52 
measurements, B. R. and M. H. d. A. clinical-chemical measurements. M. D. 
performed the Western blot analysis of signaling molecules. A. Hi. and E. W. are 
the guarantors of this work and, as such, had full access to all the data in the study 
and take responsibility for the integrity of the data and the accuracy of the data 
analysis. 
  
III. PUBLICATION       53 
5. SUPPLEMENTARY MATERIAL 
Supplementary Table 1. Antibodies employed for Western blot analyses. 
 
  
Antigen Antibody Host Dilution 
pJAK2 Cell Signaling, Frankfurt, Germany #3776 rabbit 1:2000 
JAK2 Cell Signaling, Frankfurt, Germany #3230 rabbit 1:2000 
pMAPK Cell Signaling, Frankfurt, Germany #4370 rabbit 1:2000 
MAPK Cell Signaling, Frankfurt, Germany #9102 rabbit 1:2000 
pSTAT1 Cell Signaling, Frankfurt, Germany #7649 rabbit 1:2000 
STAT1 Cell Signaling, Frankfurt, Germany #14994 rabbit 1:2000 
pSTAT3 Cell Signaling, Frankfurt, Germany #9145 rabbit 1:2000 
STAT3 Cell Signaling, Frankfurt, Germany #12640 rabbit 1:2000 
pSTAT5 Cell Signaling, Frankfurt, Germany #9359 rabbit 1:2000 
STAT5 Cell Signaling, Frankfurt, Germany #94205 rabbit 1:2000 
pPI3K Cell Signaling, Frankfurt, Germany #4228 rabbit 1:2000 
PI3K Cell Signaling, Frankfurt, Germany #4257 rabbit 1:2000 
pAKT Cell Signaling, Frankfurt, Germany #4060 rabbit 1:2000 
AKT Cell Signaling, Frankfurt, Germany #4691 rabbit 1:2000 
pmTOR Cell Signaling, Frankfurt, Germany #5536 rabbit 1:1000 
mTOR Cell Signaling, Frankfurt, Germany #2983 rabbit 1:1000 
pAMPK Cell Signaling, Frankfurt, Germany #2535 rabbit 1:2000 
AMPK Cell Signaling, Frankfurt, Germany #2532 rabbit 1:2000 
pS6K Cell Signaling, Frankfurt, Germany #9205 rabbit 1:2000 
pS6K Cell Signaling, Frankfurt, Germany #2708 rabbit 1:2000 
p4EBP1 Cell Signaling, Frankfurt, Germany #2855 rabbit 1:2000 
4EBP1 Cell Signaling, Frankfurt, Germany #9644 rabbit 1:2000 
eIF4E Cell Signaling, Frankfurt, Germany #9742 rabbit 1:2000 
PPARG Cell Signaling, Frankfurt, Germany #2435 rabbit 1:2000 
pGSK3B Cell Signaling, Frankfurt, Germany #9322 rabbit 1:2000 
GSK3B Cell Signaling, Frankfurt, Germany #9315 rabbit 1:2000 
pINSR Cell Signaling, Frankfurt, Germany #3024 rabbit 1:2000 
INSR Cell Signaling, Frankfurt, Germany #3025 rabbit 1:2000 
pIRS1 Cell Signaling, Frankfurt, Germany #3203 rabbit 1:2000 
IRS1 Cell Signaling, Frankfurt, Germany #3407 rabbit 1:2000 
pLEPR Merck, Darmstadt, Germany #07-1317 rabbit 1:500 
LEPR Bio-Rad, Munich, Germany #AHP1396 goat 1:1000 
III. PUBLICATION       54 
Supplementary Table 2. Factors affecting body fat content, muscle-to-back fat ratio, and serum leptin levels of 6-month-old 
control and GHR-KO pigs. 
Parameter 
Control GHR-KO Factors (p values) 
Sex mean SD Sex mean SD Group Sex Group*Sex 
Body fat (%) 
male 9.6 1.1 male 20.9 2.2 
< 0.0001 0.0108 0.1543 
female 13.2 2.5 female 22.0 4.1 
Muscle-to- 
back fat ratio 
(v/v) 
male 8.6 2.3 male 2.9 0.5 
< 0.0001 0.6289 0.4335 
female 7.7 2.3 female 3.1 1.3 
Serum leptin 
(µg/L) 
male 3.0 1.0 male 4.8 2.7 
0.0066 0.013 0.7437 
female 4.7 1.2 female 6.1 1.6 
The table shows means and standard deviations (SD) of means for body fat (%) and muscle to fat ratio calculated for 11 
male/14 female control pigs and for 6 male/6 female GHR-KO pigs. Means and SD for fasting serum leptin were calculated 
for 9 male/13 female control and 6 male/6 female GHR-KO pigs. Data were analyzed using the General Linear Models 
Procedure (PROC GLM) as described in section 2.8 of the main manuscript. 
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Supplementary Table 3. Organ weights of control and GHR-KO pigs.  
 Control (n = 25) GHR-KO (n = 9) % of Control p value 
Absolute weights (g) 
Liver 2315.5 ± 80.4 711.5 ± 133.9 30.6   ± 1.8 < 0.0001 
Kidneys* 335.7 ± 11.0 102.4 ± 18.4 30.7   ± 1.4 < 0.0001 
Heart 356.6 ± 9.9 133.0 ± 16.4 37.3  ± 2.1 < 0.0001 
Brain 99.3 ± 1.5 83.4 ± 2.5 84.1  ± 2.0 < 0.0001 
Lungs 686.2 ± 21.6 257.6 ± 34.9 37.1  ± 2.2 < 0.0001 
Spleen 491.6 ± 28.9 177.6 ± 48.0 36.1  ± 4.1 < 0.0001 
Pituitary gland 0.27 ± 0.01 0.13 ± 0.01 46.2  ± 1.8 < 0.0001 
Adrenal glands* 5.56 ± 0.30 2.10 ± 0.50 37.0  ± 3.0 < 0.0001 
Thyroid gland 7.45 ± 0.30 3.05 ± 0.60 40.4  ± 2.6 < 0.0001 
Relative weights (% of body weight) 
Liver 2.53 ± 0.10 1.85 ± 0.20 72.8  ± 2.8 0.0005 
Kidneys* 0.37 ± 0.01 0.27 ± 0.02 74.1  ± 3.8 0.0002 
Heart 0.39 ± 0.01 0.34 ± 0.01 89.1  ± 2.1 0.0119 
Brain 0.11 ± 0.005 0.22 ± 0.01 200.7  ± 10.0 < 0.0001 
Lungs 0.75 ± 0.03 0.68 ± 0.05 89.3  ± 6.7 0.2304 
Spleen 0.54 ± 0.03 0.46 ± 0.06 86.1  ± 9.2 0.2525 
Pituitary gland 2.90 E-4 ± 0.09 E-4 3.30 E-4 ± 0.15 E-4 110.2  ± 4.0 0.0899 
Adrenal glands* 6.10 E-3 ± 0.36 E-3 5.50 E-3 ± 0.65 E-3 88.7  ± 5.6 0.4267 
Thyroid gland 8.20 E-3 ± 0.45 E-3 8.20 E-3 ± 0.80 E-3 98.2  ± 7.7 0.9384 
Data are presented as least squares means (LSM) and standard errors (SE) of LSM estimated for the 2 
groups (the statistical model used is described in section 2.8 of the main manuscript). LSMs were compared 
using Student’s t-tests. *Cumulative weight of both organs. 
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Supplementary Table 4. Factors affecting parameters of lipid metabolism of control and GHR-KO pigs. 
Parameter Age Sex Control GHR-KO Factors (p values) 
   mean SD mean SD Group Sex Age Group*Age Group*Sex*Age 
Triglycerides 
(mg/dL) 
1 
male 40.3 16.5 20.5 6.1 
0.0113 0.2435 0.7666 0.301 0.9918 
female 44.3 20.5 25.8 10.9 
2 
male 34.8 14.6 26.2 8.1 
female 42.1 20.3 33.9 11.0 
Cholesterol 
(mg/dL) 
1 
male 76.6 7.9 61.6 4.6 
0.0851 < 0.0001 0.0535 0.0291 0.6255 
female 86.9 4.7 78.4 4.8 
2 
male 60.4 11.4 60.6 7.9 
female 78.2 10.4 81.0 6.7 
LDL (mg/dL) 
1 
male 47.1 5.8 38.3 3.9 
0.0971 < 0.0001 0.1097 0.1181 0.6526 
female 53.2 3.1 47.4 2.9 
2 
male 36.7 8.1 36.6 5.1 
female 49.2 9.8 48.9 3.4 
HDL (mg/dL) 
1 
male 31.2 3.0 26.6 4.6 
0.7111 0.0002 0.5071 0.0022 0.4577 
female 36.5 3.2 31.4 4.2 
2 
male 26.9 5.1 28.1 4.7 
female 30.3 2.2 36.9 2.9 
The table shows means and standard deviations (SD) of means calculated for 6 male/4 female control pigs and 3 male/3 female GHR-KO 
pigs at Age 1 (12-15 weeks) and for 8 male/6 female control pigs and 5 male/4 female GHR-KO pigs at Age 2 (23-27 weeks). Data were 
analyzed using the General Linear Models Procedure (PROC GLM) as described in section 2.8 of the main manuscript. 
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Supplementary Table 5. Clinical-chemical parameters of 6-month-old control and 
GHR-KO pigs. 
Parameter [unit] Control (n = 14) 
GHR-KO (n = 
9) 
p value Normal range 
Urea [mmol/L] 4.3 ± 0.3 7.4 ± 0.5 < 0.0001 3.2 – 8.2 
Creatinine [µmol/L] 126.4 ± 5.0 91.2 ± 6.5 0.0004 40 – 133 
Total protein [g/L] 65.3 ± 2.2 63.6 ± 2.9 0.6381 55 – 85 
Albumin [g/L] 40.1 ± 1.4 39.8 ± 1.8 0.8957 17.3 – 43.3 
Bilirubin [µmol/L] 1.8 ± 0.1 1.5 ± 0.2 0.2351 < 4.3 
GGT [U/L] 36.4 ± 1.8 32.5 ± 2.4 0.2131 0 – 40 
Sodium [mmol/L] 141.5 ± 1.0 139.9 ± 1.3 0.3330 133 – 150 
Potassium [mmol/L] 5.0 ± 0.2 4.2 ± 0.3 0.0602 4.4 – 6.7 
Chloride [mmol/L] 101.8 ± 0.9 99.6 ± 1.2 0.1586 95 – 110 
Calcium [mmol/L] 2.6 ± 0.04 2.7 ± 0.05 0.1744 2.4 – 3.0 
Magnesium [mmol/L] 1.1 ± 0.04 1.1 ± 0.05 0.2740 0.5 – 1.2 
Phosphorus [mmol/L] 2.4 ± 0.1 2.2 ± 0.04 0.1063 2.1 – 3.3 
Iron [µmol/L] 17.7 ± 1.2 23.6 ± 1.6 0.0094 > 17.9 
Data are presented as least squares means (LSM) and standard errors (SE) of LSM 
estimated for the 2 groups. The statistical model used is described in section 2.8 of 
the main manuscript. LSM were compared using Student’s t-test. 
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Supplementary Figure 1. Breeding scheme of GHR-KO animals. Heterozygous 
founder animals 2533 and 2539 were mated with wild-type boars and their 
heterozygous offspring were intercrossed to produce GHR-KO animals as well as 
wild-type and heterozygous GHR mutant littermates. The mating of two GHR-KO 
animals resulted in a litter of six healthy GHR-KO* piglets. 
 
Supplementary Figure 2. Body weight gain (A) and longitudinal growth (B) of 
GHR-KO (n = 12) compared to wild-type (GHR +/+; n = 6) and heterozygous GHR 
mutant (GHR +/-; n = 19) pigs. Note that there was no significant difference in 
growth of GHR +/+ and GHR +/- pigs. The two groups were thus pooled as GHR 
expressing control group.  
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Supplementary Figure 3. GH secretion profiles of additional GHR-KO (n=4) and 
control pigs (n=4). (A) Secretion pattern of two female GHR-KO and control pigs. 
(B) Secretion pattern of a female and male GHR-KO and two female control pigs. 
 
Supplementary Figure 4. GHR-KO animals are able to reproduce. Mating of a 
GHR-KO sow and GHR-KO boar resulted in a litter of healthy GHR-KO* piglets. 
(A) Picture of GHR-KO* piglets at the age of one day. (B) GHR-KO* piglets had 
lower birth weights than GHR-KO piglets from heterozygote x heterozygote 
mating, but reached a higher weight at 6 months of age (GHR-KO: n = 12, GHR-
KO*: n = 6). Data are presented as least squares means (LSM) and standard errors 
(SE) of LSM estimated for the 2 groups. The statistical model used is described in 
section 2.8 of the main manuscript. LSMs were compared using Student’s t-test. 
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Supplementary Figure 5. Western blot analysis of GHR-related signaling 
molecules in liver samples of 6-month-old fasted GHR-KO (n=5) and control pigs 
(n=4). The box plots show medians, 25th and 75th percentiles (box), and extremes 
(whiskers). * p < 0.05; evaluated using Mann-Whitney U test. 
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IV. DISCUSSION AND OUTLOOK 
Beneficial effects resulting from GHRD are reported for human patients, regarding 
increased insulin sensitivity while facing severe obesity, protection against the 
development of malignancies as cancer and longevity-associated effects, the 
investigation of underlying mechanisms is promising. As human cases are spread 
world-wide and caused by different mutations and the use of the murine model is 
limited by physiological differences from humans, our GHR-KO pig can provide 
further insight into the consequences of GHRD. We show, that the generation of a 
GHR knockout was successfully performed applying the CRISPR/Cas9 technology 
in zygotes and that GHR-KO pigs resemble the endocrine, auxologic and metabolic 
phenotype of the human LS. Future investigations involving the GHR-KO pig 
overcoming limitations in mice are outlined. 
1. GHR-KO was successfully generated by CRISPR/Cas 
As outlined in detail in the review of the literature, the main difference of the 
pathophysiology of the Laron syndrome in contrast to other forms of dwarfism is 
the inability of the GHR to bind circulating GH or to signal due to mutations of the 
GHR gene (Eshet, Laron et al. 1984). We chose the CRISPR/Cas9 technology to 
induce mutations in exon 3 of the porcine GHR gene, as its application is widely 
emerging in the generation of transgenic animal models, providing target-site 
directed mutations which are transmitted through the germ-line (reviewed in 
Dmochewitz and Wolf 2015). By PCR and sequencing analysis of the GHR exon 3 
of F2 generation offspring (Figure 4), we identified the target-site mutation. The 
sequencing analysis of the mutated GHR sequence revealed a shift of the reading 
frame leading to the establishment of premature termination codons predicting a 
non-functional GHR protein in GHR-KO animals. Our approach to investigate the 
direct binding capacity of exogenous GH proved that our GHR-KO animals exhibit 
a hallmark of the human LS, showing no binding capacity of GH. Furthermore, we 
can exclude any kind of remnant GH signaling, which is a limitation in the minipig 
model expressing a dominant negative GHR (Li, Li et al. 2015) with still functional 
GH signaling via residue wild-type GHRs leading to a form of intermediate 
phenotype.  
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Figure 4. 1Applying the CRISPR/Cas9 technology, a 7-bp and 
1-bp insertion has been introduced in exon 3 of the porcine GHR 
gene. F2 animals were obtained by breeding exhibiting the 
mutated GHR gene sequence specific for each line (marked as 
boxes). 
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2. GHR-KO pigs exhibit the phenotype of Laron syndrome 
To overcome physiologic limitations in mice, we chose to generate our large animal 
model for LS on the genetic background of the German landrace pig breed. Other 
pig models for LS were established on minipig backgrounds (Cui, Li et al. 2015, 
Li, Li et al. 2015), where abnormalities of the endocrine growth regulatory axis may 
be suspected, as the proportional growth retardation of minipigs resembles the 
phenotype of pituitary dwarfism, such as GH or IGF1 deficiency (Simianer and 
Köhn 2010). In contrast, we chose a pig 
breed without a selection for dwarf size. 
As the maturation of the endocrine growth 
axis appears similar in pigs as in humans 
– in contrast to rodents, both are born with 
a fully mature endocrine growth axis 
involving the characteristic shift in 
growth promoting hormones (Savage, 
Blum et al. 1993) - GHR-KO pigs 
resemble the auxologic phenotype of the 
human LS (reviewed in Rosenfeld, 
Rosenbloom et al. 1994), showing no 
significant differences at birth but severe 
postnatal growth retardation (Figure 5) 
due to the shift from intrauterine GH 
independent growth promotion by IGF2 
and IGF1 towards postnatal GH 
dependent growth promotion by IGF1 
(Baker, Liu et al. 1993) (Hetz, Menzies et 
al. 2015). The lack of IGF1 is obvious in 
GHR-KO pigs of all ages and results in 
elevated levels of circulating GH. While 
other studies in GHR deficient animal 
models describe elevated GH levels by 
analyzing a single sample (Zhou, Xu et al. 
1997, Cui, Li et al. 2015) disregarding the pulsatility of GH secretion, we evaluated 
the changes in GH levels over a longer period of time as performed in human 
Figure 5. 1GHR-KO (marked by 
asterisk) and control littermates at 
top to bottom: 1 day; 1 month, 
2 months, 6 months of age 
IV. DISCUSSION AND OUTLOOK     75 
patients with LS (Keret, Pertzelan et al. 1988). Long-term serum GH levels of 
GHR-KO pigs were significantly higher than control animal’s values and displayed 
partially preserved pulsatility. It remains unclear, why the levels in GHR-KO pigs 
do not completely represent the exceeding peaks of GH secretion in human LS 
patients observed especially after meals or during sleep (Keret, Pertzelan et al. 
1988). Nevertheless, a continuous blood sampling should be performed 
preferentially in pigs than mice as the placement of the central venous catheter takes 
place with minimal-invasive methods and the stress induced to the animals can be 
reduced by training (Kleinert, Clemmensen et al. 2018).  
Regarding the growth of organs, GHR-KO pigs represent the phenotype seen in 
humans (Feinberg, Scheinowitz et al. 2000) (Backeljauw and Underwood 2001) 
and mice (Sjogren, Bohlooly et al. 2000, Berryman, List et al. 2006, Berryman, List 
et al. 2010), highlighting the different dependence on GH action of specific tissues 
resulting in proportional and disproportional reduction of organ weights.  
A high proportion of body fat is a hallmark of the human LS and is referred to as 
obesity. While Ghr KO mice display a high abundance in total body fat, which was 
estimated in DXA analyses (Egecioglu, Bjursell et al. 2006), in depth investigations 
revealed an enlargement of specific fat depots, notably of subcutaneous fat (Flint, 
Binart et al. 2006), while epididymal fat pats, which are preferentially investigated 
in mice, were not enlarged (Berryman, List et al. 2004). The interpretation of the 
relative increase in adipose tissue in the Ghr KO mice remains complicated as it 
may be seen as the fat tissue being not affected by GHRD, while other tissues show 
growth impairment due to the lack of GH action (reviewed by Berryman in Laron 
and Kopchick 2011, List, Sackmann-Sala et al. 2011) or the lack of GH and/or IGF1 
action leads to a progression of fat accumulation, referred to as obesity in human 
LS patients (Laron, Ginsberg et al. 2006). In line with the observations in humans 
and mice, GHR-KO pigs displayed a high percentage of body fat, leading to the 
investigation of effects on metabolism and especially glucose homeostasis, as 
differences between the human cohorts of LS patients are occurring.  
As outlined in the review of the literature, transient juvenile hypoglycemia is a 
common symptom of LS, but the Israeli cohort exhibits a progressing glucose 
intolerance and even cases of diabetes mellitus (Laron, Avitzur et al. 1997), while 
the Ecuadorian cohort remains insulin sensitive (Guevara-Aguirre, Rosenbloom et 
al. 2015). To get first insights into changes in insulin sensitivity of GHR-KO pigs, 
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we investigated the fasting blood glucose and insulin levels of animals aged 12-15 
weeks representing young individuals with LS and animals aged six months, 
representing adults. Just as seen in the human and murine phenotype, low fasting 
blood glucose levels were observed at young ages, which increased and became 
similar to control animal`s values when reaching the age of six months. The 
measurements of insulin levels and the calculation of the HOMA-IR score revealed 
no pathologic alterations in insulin sensitivity, as the rise in HOMA-IR score 
represents the increase in glucose levels, and never reaches even the lowest values 
being seen critical for humans (reviewed in Tang, Li et al. 2015). These results 
indicate, that GHR-KO pigs do not represent the Laron phenotype of the 
Israelicohort, with a progressive decrease in insulin sensitivity resulting in diabetes 
mellitus. They rather exhibit the phenotype observed in the Ecuadorian cohort, 
including an increased insulin sensitivity and protection from the development of 
diabetes mellitus (Guevara-Aguirre, Rosenbloom et al. 2015). For further proof, we 
investigated the insulin receptor associated signaling pathways in liver tissue 
derived from fasted animals aged six months and revealed an increased expression 
and phosphorylation of IRS1 and downstream signal transducers of the insulin 
receptor, suggesting an increase in insulin signaling and sensitivity. While those 
observations point towards the “Ecuadorian phenotype” being represented by 
GHR-KO pigs, we are in need for further analyzes, which are outlined as future 
perspectives.  
3. Altered activation of hepatic signaling cascades 
Hepatic signaling studies were performed from tissue derived from fasted six 
months old GHR-KO and control animals, investigating insulin receptor associated, 
metabolic pathways and signaling associated with the GHR.  
The observed activation of insulin receptor associated signaling cascades and 
transient juvenile hypoglycemia while insulin levels were normal point towards 
increased insulin sensitivity, which is a major positive effect of GHRD, protecting 
LS patients from developing diabetes even whilst facing severe obesity (Guevara-
Aguirre, Rosenbloom et al. 2015)). As LS patients seem to be protected from the 
development of malignancies (reviewed in Laron, Kauli et al. 2017) and show 
increased longevity (Shevah and Laron 2007), a connection between our findings 
in the GHR-KO pig model and results from the “Leiden longevity study” seems 
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appropriate. In this study, nonagenarian siblings with a low mortality rate were 
compared to their offspring and partners (Westendorp, van Heemst et al. 2009). 
Investigations showed a correlation between a reduced insulin and IGF signaling 
and longevity but resulting in shorter stature (Van Heemst, Beekman et al. 2005), 
similar to findings in our animal model. Furthermore, the authors noted a 
tremendous effect of the activity of the mechanistic target of rapamycin (mTOR) 
signaling mediating lifespan extension (Slagboom, Beekman et al. 2011). As 
outlined in detail in the review of the literature, mTOR is seen as “sensing” the 
nutritional status of the organism and regulating anabolic or catabolic activity on 
cellular levels and a chronic activation of the mTORC1 resulting from over-feeding 
diets is seen to induce the onset of diabetes mellitus (reviewed in Zoncu, Efeyan et 
al. 2011). Similar to findings in humans, the analysis of downstream signaling 
pathways showed an increased activity of mTORC2, contributing to beneficial 
effects on metabolism (Guevara-Aguirre, Balasubramanian et al. 2011), while 
mTORC1 associated signaling showed no alterations in GHR-KO pigs.  
Both findings, a suggested increase in insulin sensitivity and an increase in 
mTORC2 signaling, suggest beneficial effects on longevity of GHR-KO pigs, 
which raises the need for further investigations. 
Results from hepatic GHR-associated signaling cascades appeared surprising at 
first sight. At a state of GHRD, it would have been expected, that the activity of 
STAT5 and JAK2 should be diminished, as those are the signal transducers of GH 
action (reviewed in Waters 2015). In line with that, the phosphorylation levels of 
STAT5 were significantly reduced in GHR-KO pigs, but levels of phosphorylated 
JAK2 were increased. In fact, investigations of LS patients and the Ghr KO mouse 
did not include the phosphorylation status of STAT5 and JAK2 on a routine base, 
neither was a significant decrease in STAT5 and JAK2 mRNA expression observed 
in other animal models for LS (Cui, Li et al. 2015). While an activation of JAK2 by 
residual functional GHRs could be excluded by ligand immunostainings of liver 
and kidney sections of GHR-KO pigs, its activation by other cytokine receptors 
seemed likely. A potential candidate was the leptin receptor as its activation induces 
the phosphorylation of STAT3 by JAK2 (reviewed in Rawlings, Rosler et al. 2004), 
whose phosphorylation levels were not decreased in GHR-KO pigs, and further 
increased fasting serum leptin levels were observed in GHR-KO pigs in line with 
findings in human LS patients (Laron, Silbergeld et al. 1998) and the Ghr KO 
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mouse (reviewed in List, Sackmann-Sala et al. 2011).  
Showing that the phosphorylation levels of hepatic leptin receptors were in fact 
increased in GHR-KO and potentially lead to the observed JAK2 activation was a 
major finding of our study, since this connection in the context of GHRD has never 
been described before.  
4. Future investigations 
Our recent publication represents a first characterization of the GHR-KO pig model. 
While we gained insight into the effects of GHRD and successfully characterized 
endocrine alterations, it remains necessary to perform detailed investigations of 
effects on bone growth and formation of the epiphyseal growth plate. Further, in 
depth analysis of the pituitary gland as a target organ for endocrine feedback 
mechanisms seems promising. As alterations in glucose homeostasis and hepatic 
signaling provide potential beneficial effects of GHRD, an increase of insulin 
sensitivity in GHR-KO pigs needs to be proven and longevity associated analysis 
should follow. In contrast to the Ghr KO mice (Danilovich, Wernsing et al. 1999), 
no deficits in fertility of GHR-KO pigs were observed; thus large numbers of 
animals homozygous for the mutation can be maintained by mating of GHR-KO 
sows and boars for future experiments. 
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4.1. Bone growth 
Investigating a dwarf phenotype, it appears obvious to perform detailed analyses of 
epiphyseal growth plates to determine the changes in bone formation leading to 
growth retardation. As longitudinal growth is physiological terminated by the 
epiphyseal closure, a porcine model appears more suitable than rodent models in 
representing human conditions. In mice and rats, bone growth persists throughout 
a large proportion of their life expectancy, after the animals are referred to as adults. 
In contrast, the growth plate is already closed in adult 
humans (reviewed in Kilborn, Trudel et al. 2002) 
induced by sexual maturity (Isaksson, Lindahl et al. 
1987) Luckily, the pig is seen as the “species of 
choice” for representing human bone physiology, as 
close similarities are reported regarding anatomy, 
morphology, healing, remodeling and specifically 
bone mineral density (BMD) and mineral content 
(reviewed in Pearce, Richards et al. 2007), which is 
of particular interest in the context of LS. Besides a 
reduction of the width of the epiphyseal plate, 
reduced BMD is reported for Ghr KO mice (reviewed 
in List, Sackmann-Sala et al. 2011). In line with that, 
a reduction of absolute BMD is reported for human 
LS patients (Shaw, Fraser et al. 2003), but appears 
normal when corrected for bone volume (reviewed in Laron, Kauli et al. 2017). As 
expected, the length of all bones is reduced (Figure 6) and data from DXA analyzes 
of overall bone structure revealed reduced BMD (Figure 7) in GHR-KO pigs. A 
further investigation should include the comparison of data from GHR-KO pigs to 
control animals of the same weight and an analysis of the BMD of particular bones, 
which can easily be done with the existing images.  
 
Figure 6. 2GHR-KO pigs 
exhibit shorter bones. 
Tibia, femur and skulls of 
control (left) and GHR-
KO animals (right) aged 
six months 
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The determination of BMD of selected preserved bones by microCT scans as 
performed in the Ghr KO mouse (Berryman, List et al. 2010) can be useful. The 
increase in levels of serum alkaline phosphatase in GHR-KO pigs aged six months 
(Figure 7) can be of further interest, as increased levels can indicate active 
remodeling processes of bones involving the activity of osteoblast, which are 
usually seen at younger ages (Kraft 2005).  
A connection between bone remodeling processes and metabolism can be effecting 
the LS phenotype, as recent studies revealed the influence of osteoblast metabolism 
on energy utilization affecting the body composition (Fulzele, Riddle et al. 2010).  
4.2. Alterations on pituitary levels 
As the source of circulating GH and its involvement in complex endocrine feedback 
mechanisms (reviewed in Varela-Nieto and Chowen 2005), the pituitary gland is an 
organ of specific interest concerning GHRD. Besides the determination of the 
weight of pituitary glands of GHR-KO and control animals, we preserved manifold 
unpublished data and samples during the preparation of this study for future 
investigations, including pituitary diameters, formalin-fixed pituitary glands and 
hypothalamic tissues for histological and immunohistological analyses, tissue 
samples at -80°C for signaling studies, RNA sequencing or proteomic studies and 
tissue samples for electron microscopy. In line with observations in GHR-KO pigs, 
imaging analysis of pituitary glands of human LS patients revealed neither 
alterations in size, nor pathologic abnormalities (Kornreich, Horev et al. 2003). In 
spite of the impaired feedback inhibition of GH secretion in GHRD, the partially 
preserved pulsatility of GH secretion could be a reason why somatotroph 
hyperplasia was not observed (reviewed in Laron and Kopchick 2011). A suitable 
way to investigate this hypothesis, would be the investigation of compartments of 
Figure 7. 3DXA analysis of a GHR-KO pig aged six months 
during the preparation of this study. BMD is significantly 
decreased while serum alkaline phosphatase levels were 
elevated.  
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the pituitary glands of GHR-KO pigs using stereological methods (as described in 
(Albl, Haesner et al. 2016)), which of course cannot be performed in human 
patients. Similar investigations have been performed in the Ghr KO mouse 
revealing an increase in GH-immunoreactive cells and hyperplasia of granulated 
cells in electron microscopy (Asa, Coschigano et al. 2000). The immunostaining of 
GH performed in our study can easily be applied for the detection of GH-
immunoreactive cells in the pituitary glands of GHR-KO pigs and a signaling 
studies can provide further insight on GHR-signaling associated alterations on 
pituitary and hypothalamic levels. 
4.3. Longevity studies 
A potential hindrance of the use of a pig model occurs when effects on longevity 
are studied. A simple estimation of the pig`s life expectancy as performed for the 
Ghr KO mouse (Bartke and Brown-Borg 2004) would consume way too much time. 
Potential approaches would be the in vitro estimation of stress resistance or the 
cross-breeding of GHR-KO pigs with genetically engineered pig strains harboring 
pathologic insults. The cellular resistance towards exogenous stress in in vitro 
studies is a well-established indicator for extended longevity (reviewed in Johnson, 
Lithgow et al. 1996). A suitable application to estimate longevity-associated effects 
in GHR-KO pigs would be the reproduction of the work of Murakami et al. 
(Murakami, Salmon et al. 2003), who found fibroblast derived from Snell dwarf 
mice being more resistant to cellular stress such as UV light, heat or H2O2. A study 
involving the cross-breeding of Ghr KO mice with a mouse strain developing 
prostatic neoplasia (called Tag) showed that while seven of eight Tag animals with 
intact GHR signaling showed neoplastic lesions, only one of eight Tag x Ghr KO 
mice exhibited those, suggesting impaired tumor growth in GHRD (Wang, Prins et 
al. 2005). As mouse models show several limitations in cancer research concerning 
longitudinal studies of tumor progression and remission, genetically tailored pig 
models developing neoplasia became more widely used (reviewed in Flisikowska, 
Kind et al. 2014). A possible candidate for the cross-breeding with GHR-KO pigs 
would be the APC1061-pig (Flisikowska, Merkl et al. 2012), which develops 
adenomatous polyps in the colon and rectum, whose progression can be easily 
followed by colonoscopy. 
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4.4. Insulin sensitivity 
The phenotype of the Ecuadorian cohort of LS patients is of specific interest, as it 
is characterized by increased insulin sensitivity in spite of severe obesity (Guevara-
Aguirre, Rosenbloom et al. 2015). As obesity and diabetes are a major health 
problem in Western and developing societies (Ng, Fleming et al. 2014), the 
investigation of metabolic alterations of our GHR-KO pig seems promising, as it 
resembles the phenotype of this cohort of LS patients. Further, the pig is well 
established as an animal model for studying metabolic effects associated with 
diabetes (reviewed in Wolf, Braun-Reichhart et al. 2014) and a variety of methods 
generating meaningful data can be applied (reviewed in Renner, Dobenecker et al. 
2016). Analysis should be performed in the young (12-15 weeks of age) and adult 
(six months of age) age group of GHR-KO pigs to address the phenomenon of 
transient juvenile hypoglycemia and reveal underlying mechanisms. For the 
investigation of insulin sensitivity, intravenous glucose tolerance tests (ivGTT) 
(Renner, Fehlings et al. 2010) or hyperinsulinemic, euglycemic clamp studies 
(Lang, Vaugelade et al. 1999) can easily be performed in large animal models. A 
tissue sampling for signaling analysis should include beside liver, muscle and fat 
tissue, due to their involvement in glucose metabolism and insulin sensitivity 
(reviewed in Saltiel and Kahn 2001). Muscle and fat tissue can easily be taken 
during the placement of central venous catheters for clamp studies, liver biopsies 
can be taken ultrasound-guided (Kessler 2000)). Besides signaling studies as 
performed in our recent publication including insulin receptor, mTOR and GHR 
associated signaling cascades, effectors of gluconeogenesis such as 
phosphoenolpyruvate carboxykinase (PEPCK) (reviewed in Chung, Chacko et al. 
2015) should be included, as a lack of stimulatory GH effects on hepatic 
gluconeogenesis is expected (reviewed in Vijayakumar, Novosyadlyy et al. 2010).  
4.5. Treatment trials 
Data from both cohorts suggest, that LS patients do not benefit from positive effects 
of GHRD (Guevara-Aguirre, Balasubramanian et al. 2011, Laron and Kopchick 
2011), as their appearance as growth retarded accompanied by obese physic and 
mental retardation in the Israeli cohort (Shevah, Kornreich et al. 2005) leads to 
socioeconomic marginalization, resulting in an increase of alcohol abuse (Junnila, 
List et al. 2013), making a suitable treatment desirable. As outlined in detail in the 
review of the literature, the treatment with recombinant biosynthetic IGF1 can 
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increase the growth velocity in infants and modify the physic appearance, but needs 
to be administered on a daily base due to short half-life and severe adverse effects 
are reported. As reviewed by Aigner et al. the use of pig models for the development 
of new therapies and drugs emerges, as moue models are limited in generating 
reliable data on efficiency and safety of new therapeutic approaches (Aigner, 
Renner et al. 2010). As the GHR-KO pig resembles the human phenotype of LS, it 
can be used to improve the treatment of the human syndrome. A major disadvantage 
of the existing treatment lies in the short half-life of recombinant IGF1, as most 
adverse effects are due to over dosage or administration without food. A suitable 
way to increase the half-life of recombinant IGF1 can be the PASylation technology 
(Schlapschy, Binder et al. 2013), where in brief the fusion of proline, alanine and 
serine (PAS) polypeptides to a therapeutic protein increases its half-life by a 
reduction of renal clearance due to increased hydrodynamic volume of the synthetic 
drug.  
 
In conclusion, the GHR-KO pig represents the human phenotype, particularly of the 
Ecuadorian cohort regarding glucose homeostasis and provides a suitable model 
for the investigation of metabolic changes. To gain further insight on beneficial 
effects of GHRD from the GHR-KO pig and the development of new therapeutic 
options for the human syndrome is desirable.  
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V. SUMMARY 
The Laron syndrome (LS) is an autosomal recessive hereditary human disorder with 
just a few hundred cases world-wide. Due to a mutation of the GHR gene, the 
binding capacity of circulating GH or the signal transduction is diminished, 
resulting in a decreased production of IGF1 by the liver and elevated serum GH 
levels due to the lack of regulatory feedback mechanism. Affected patients suffer 
from severe postnatal growth retardation leading to a dwarf phenotype. 
Furthermore, severe juvenile hypoglycemia and an increase in body fat are 
hallmarks of the human LS. Observations revealed a protection from malignancies 
such as cancer and increased insulin sensitivity is reported from a genetically 
homogenous cohort of LS patients from Ecuador.  
A rodent model for LS, the Ghr KO / Laron mouse was established in 1997 and 
showed increased life expectancy resulting from growth hormone receptor 
deficiency (GHRD). While the Ghr KO mouse resembles hallmarks of the human 
phenotype, its usage is limited by evolutionary differences to humans concerning 
the endocrine growth stimulation and bone formation.  
As porcine models are able to bridge (patho)physiological gaps between rodent 
models and human diseases and emerge as a useful tool in translational medicine, 
we generated a pig model for LS by target site mutation of the porcine GHR exon 
3 applying the CRISPR/Cas9 technology. The GHR-KO pig resembles hallmarks 
of the human disease phenotype and our study revealed altered activation of hepatic 
signaling cascades. The endocrine changes in the GHR-KO pig result from a 
diminished binding of GH and include decreased levels of serum IGF1 and 
IGFBP3, while GH and IGFBP2 levels were increased similar to human LS 
patients. The characterization of the pig model further included auxologic and 
metabolic analyses and revealed postnatal growth retardation leading to a body 
weight of 60% of control animal´s weight at an age of six months. Furthermore, 
GHR-KO pigs displayed an increase in body fat and proportional and 
disproportional reduction in organ weights as reported for human LS patients and 
the murine model. The investigation of metabolic characteristics revealed transient 
juvenile hypoglycemia while insulin levels remained similar to control animal`s 
values.  
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To determine a state of increased insulin sensitivity, we investigated insulin 
receptor associated signaling pathways in liver samples derived from fasted animals 
aged six months and observed an increased abundance and phosphorylation of IRS1 
and increased activity of other signal transducers. An increase in insulin receptor 
associated signaling in animals with normal fasting serum insulin levels suggests 
an increase in insulin sensitivity in GHR-KO pigs as seen in human patients from 
the Ecuadorian cohort who are protected from developing diabetes. As 
hyperactivation of the mTORC1 is commonly seen in association with the 
development of cancer, while mTORC2 is preferentially involved in cell 
homeostasis, the increase in mTORC2 but not mTORC1 activity in GHR-KO pigs 
can be seen as a positive effect of GHRD. As expected, the investigation of GHR 
associated signaling cascades revealed decreased phosphorylation STAT5. We 
were able to explain the increased phosphorylation of JAK2 by an increased 
signaling of the leptin receptor accompanied with elevated serum leptin levels.  
In conclusion, we successfully generated a novel large animal model for LS, which 
can provide further insight on the molecular basis of the disease and can be used 
for the development of new therapeutic approaches.  
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VI. ZUSAMMENFASSUNG 
Erstellung und Charakterisierung eines Schweinemodells für das Laron 
Syndrom 
Das Laron Syndrom (LS) ist eine autosomal rezessiv vererbte Erkrankung, von der 
weltweit nur wenige hundert Personen betroffen sind. Die Mutation des 
Wachstumshormon-Rezeptor (GHR) Gens führt dazu, dass Wachstumshormon 
(GH) nicht gebunden werden kann oder dass die Signalkaskade gestört ist. Daraus 
resultiert eine verminderte Bildung von IGF1 durch die Leber und eine Erhöhung 
der Serum-GH-Spiegel aufgrund des Fehlens regulatorischer Feedback- 
Mechanismen. Die Patienten sind von einer postnatalen Wachstumsretardierung 
betroffen, die zu Minderwuchs führt. Des Weiteren sind eine dramatische 
Hypoglykämie bei Kindern und Zunahme von Körperfett charakteristisch für das 
Laron Syndrom. Untersuchungen ergaben, dass Betroffene vor einigen 
Erkrankungen, insbesondere Krebs, geschützt zu sein scheinen. Des Weiteren 
wurde in einer genetisch sehr homogenen Population von Laron Syndrom Patienten 
aus Ecuador eine erhöhte Insulin-Sensitivität beobachtet.   
Im Jahr 1997 wurde das erste Nager-Modell für LS - die Ghr KO/Laron Maus - 
erstellt. An ihr wurde gezeigt, dass GHR-Defizienz (GHRD) die Lebenserwartung 
deutlich erhöht. Während die Ghr KO Maus die meisten Charakteristika des 
humanen Phänotyps wiederspiegelt, ist ihr Nutzen durch physiologisch 
Unterschiede zum Menschen begrenzt. Dies betrifft vor Allem die endokrine 
Steuerung des Wachstums und insbesondere die Physiologie der Knochen. 
Da Schweine-Modelle in der Lage sind, Lücken zwischen Grundlagenstudien an 
Nager-Modellen und klinischen Studien zu schließen und im Rahmen der 
translationalen Medizin zunehmend an Bedeutung gewinnen, haben wir mittels der 
CRISPR/Cas9 Technologie ein Schweine-Modell für das Laron Syndrom erstellt, 
indem wir eine zielgerichtete Mutation des GHR Exons 3 erzeugt haben. Das 
GHR-KO Schwein gibt die Charakteristika des humanen Phänotyps wieder und 
Analysen von Leberproben ergaben eine veränderte Aktivität von Signalkaskaden. 
Die fehlende Bindung von Wachstumshormon bei den GHR-KO Schweinen führt 
zu weitreichenden Veränderungen auf endokrinologischer Ebene, die auch im 
humanen Phänotyp vorhanden sind. Während die Serum-Spiegel von IGF1 und 
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IGFBP3 reduziert waren, wurden erhöhte Konzentrationen von zirkulierendem 
Wachstumshormon und IGFBP2 gemessen. Die Charakterisierung der GHR-KO 
Schweine beinhaltete auxologische und metabolische Veränderungen. Unsere 
Studie zeigt, dass die postnatale Wachstumsretardierung dazu führt, dass das 
Gewicht der GHR-KO Schweine im Alter von 6 Monaten nur 60% des Gewichtes 
von Kontrolltieren erreicht. Des Weiteren wurde eine deutliche Zunahme an 
Körperfett und eine proportionale und disproportionale Reduzierung von 
Organgewichten registriert. Die Beobachtungen entsprechen dem menschlichen 
Phänotyp und Ergebnissen aus dem Maus-Modell. Junge GHR-KO Tiere zeigten 
eine deutliche Hypoglykämie, während die Plasma-Glukose-Werte von 6 Monate 
alten GHR-KO Schweinen im Bereich sich nicht von denen altersgleich 
Kontrolltiere unterschieden. Während der gesamten Entwicklung zeigten sich keine 
signifikanten Unterscheide der gefasteten Insulin Werte zwischen GHR-KO und 
Kontrolltieren.  
Zur Bestätigung einer gesteigerten Insulin-Sensitivität untersuchten wir 
Signalkaskaden, die mit dem Insulinrezeptor in Verbindung stehen, in Leberproben 
von 6 Monate alten, gefasteten Tieren. Es zeigte sich eine erhöhte Abundanz und 
Phosphorylierung des IRS1 und weiterer Signalüberträger. Die erhöhte Aktivität 
von Insulinrezeptor-assoziierten Signalkaskaden bei normalen gefasteten Insulin-
Werten weist auf eine erhöhte Insulin-Sensitivität der GHR-KO Schweine hin. Dies 
wurde auch bei ecuadorianischen Laron Syndrom Patienten beobachtet, die keinen 
Diabetes entwickeln. Als weiteren positiven Effekt von GHRD wurde bei den 
GHR-KO Schweinen eine verstärkte Aktivität von mTORC2 beobachtet, während 
die Aktivität von mTORC1, das häufig im Zusammenhang mit der Entwicklung 
von Krebs gesehen wird, weitestgehend ausgeschlossen werden kann. Wie zu 
erwarten zeigte die Untersuchung von Signalkaskaden im Zusammenhang mit dem 
GHR eine reduzierte Phosphorylierung von STAT5. Insbesondere waren wir in der 
Lage, eine erhöhte Phosphorylierung von JAK2 mit erhöhten Serum- Leptin-
Werten sowie einer vermehrten Expression und Aktivierung von Leptin-
Rezeptoren in der Leber in Zusammenhang zu bringen. 
Zusammenfassend stellt das GHR-KO Schwein ein interessantes Großtiermodell 
für das Laron Syndrom dar, an dem weitere Einsichten in die molekularen 
Mechanismen der Erkrankung gewonnen sowie neue therapeutischer Ansätze 
entwickelt und getestet werden können.  
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